US20220372013A2 - Piperidine-2,6-dione derivatives and crohn's disease treating - Google Patents
Piperidine-2,6-dione derivatives and crohn's disease treating Download PDFInfo
- Publication number
- US20220372013A2 US20220372013A2 US16/464,228 US201716464228A US2022372013A2 US 20220372013 A2 US20220372013 A2 US 20220372013A2 US 201716464228 A US201716464228 A US 201716464228A US 2022372013 A2 US2022372013 A2 US 2022372013A2
- Authority
- US
- United States
- Prior art keywords
- dione
- pharmaceutically acceptable
- acceptable salts
- dioxopiperidin
- isoindolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000005459 piperidine-2,6-diones Chemical class 0.000 title claims abstract description 72
- 208000011231 Crohn disease Diseases 0.000 title claims abstract description 70
- 150000003839 salts Chemical class 0.000 claims description 207
- 239000007787 solid Substances 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 43
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 239000003826 tablet Substances 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- YJIGIPFJUWIKGT-UHFFFAOYSA-N 4-amino-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1N(CCOC)C(=O)CCC1N1C(=O)C2=C(N)C=CC=C2C1=O YJIGIPFJUWIKGT-UHFFFAOYSA-N 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000008298 dragée Substances 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 9
- GRUCKRQQDPQFSZ-UHFFFAOYSA-N 4-amino-2-[1-(2-methylsulfanylethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)CCSC)=O)=O GRUCKRQQDPQFSZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- ZADSTGFMEUUWGX-UHFFFAOYSA-N 4-amino-2-[1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1N(CCOCC)C(=O)CCC1N1C(=O)C2=C(N)C=CC=C2C1=O ZADSTGFMEUUWGX-UHFFFAOYSA-N 0.000 claims description 7
- CCMRGGGYISCMSR-UHFFFAOYSA-N 4-amino-2-[1-(2-methoxyethyl)-3-methyl-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1)=O)C1(C(N(C(CC1)=O)CCOC)=O)C)=O CCMRGGGYISCMSR-UHFFFAOYSA-N 0.000 claims description 7
- QSNJRAIQVBGDIS-UHFFFAOYSA-N 4-amino-2-[1-(2-methylsulfinylethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)CCS(=O)C)=O)=O QSNJRAIQVBGDIS-UHFFFAOYSA-N 0.000 claims description 7
- WEZXXQKONKSBAB-UHFFFAOYSA-N 4-amino-2-[3-fluoro-1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1)=O)C1(C(N(C(CC1)=O)CCOC)=O)F)=O WEZXXQKONKSBAB-UHFFFAOYSA-N 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- ZHYBYDOGOPRYIB-UHFFFAOYSA-N 2-[1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl]-4-fluoroisoindole-1,3-dione Chemical compound FC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)CCOCC)=O)=O ZHYBYDOGOPRYIB-UHFFFAOYSA-N 0.000 claims description 6
- NNWZQFYWTTZJHH-UHFFFAOYSA-N 2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]-4-(methylamino)isoindole-1,3-dione Chemical compound O=C1C=2C(NC)=CC=CC=2C(=O)N1C1CCC(=O)N(CCOC)C1=O NNWZQFYWTTZJHH-UHFFFAOYSA-N 0.000 claims description 6
- WCZAFKBRYWUCEF-UHFFFAOYSA-N 2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]-4-methylisoindole-1,3-dione Chemical compound COCCN1C(=O)CCC(N2C(=O)c3cccc(C)c3C2=O)C1=O WCZAFKBRYWUCEF-UHFFFAOYSA-N 0.000 claims description 6
- MOBCMXHKIZSDOH-UHFFFAOYSA-N 4,5,6,7-tetrafluoro-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1N(CCOC)C(=O)CCC1N1C(=O)C(C(F)=C(F)C(F)=C2F)=C2C1=O MOBCMXHKIZSDOH-UHFFFAOYSA-N 0.000 claims description 6
- NKWILXXHUUDKOX-UHFFFAOYSA-N 4-(dimethylamino)-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1N(CCOC)C(=O)CCC1N1C(=O)C2=C(N(C)C)C=CC=C2C1=O NKWILXXHUUDKOX-UHFFFAOYSA-N 0.000 claims description 6
- GVCHRTBIKPLXMJ-UHFFFAOYSA-N 4-amino-2-[1-(2-hydroxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)N(CCO)C1=O GVCHRTBIKPLXMJ-UHFFFAOYSA-N 0.000 claims description 6
- LCNRZCVLTLTPHP-UHFFFAOYSA-N 4-amino-2-[1-(2-methylsulfonylethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)CCS(=O)(=O)C)=O)=O LCNRZCVLTLTPHP-UHFFFAOYSA-N 0.000 claims description 6
- PMKKVCHHHBGNGX-UHFFFAOYSA-N 4-amino-5-fluoro-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1F)=O)C1C(N(C(CC1)=O)CCOC)=O)=O PMKKVCHHHBGNGX-UHFFFAOYSA-N 0.000 claims description 6
- URTDCNHXPBJDQC-UHFFFAOYSA-N 4-amino-5-hydroxy-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1O)=O)C1C(N(C(CC1)=O)CCOC)=O)=O URTDCNHXPBJDQC-UHFFFAOYSA-N 0.000 claims description 6
- NRZURXUBBFJBSZ-UHFFFAOYSA-N 4-amino-7-hydroxy-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=C(C=C1)O)=O)C1C(N(C(CC1)=O)CCOC)=O)=O NRZURXUBBFJBSZ-UHFFFAOYSA-N 0.000 claims description 6
- PZSGXZMCORYEMH-UHFFFAOYSA-N 4-fluoro-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1N(CCOC)C(=O)CCC1N1C(=O)C2=C(F)C=CC=C2C1=O PZSGXZMCORYEMH-UHFFFAOYSA-N 0.000 claims description 6
- QUMLVJUSXZISEY-UHFFFAOYSA-N 4-hydroxy-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound OC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)CCOC)=O)=O QUMLVJUSXZISEY-UHFFFAOYSA-N 0.000 claims description 6
- GWDLJKSZNLIRDU-UHFFFAOYSA-N 5-amino-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1N(CCOC)C(=O)CCC1N1C(=O)C2=CC(N)=CC=C2C1=O GWDLJKSZNLIRDU-UHFFFAOYSA-N 0.000 claims description 6
- SPKUGKYJZSZFIB-UHFFFAOYSA-N 5-fluoro-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound FC=1C=C2C(N(C(C2=CC=1)=O)C1C(N(C(CC1)=O)CCOC)=O)=O SPKUGKYJZSZFIB-UHFFFAOYSA-N 0.000 claims description 6
- JNIONTLWTIDMFG-UHFFFAOYSA-N N-[2-[1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C(C)(=O)NC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)CC(C)OC)=O)=O JNIONTLWTIDMFG-UHFFFAOYSA-N 0.000 claims description 6
- NUALQIPEWVUAOO-UHFFFAOYSA-N n-[2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound O=C1N(CCOC)C(=O)CCC1N1C(=O)C2=C(NC(C)=O)C=CC=C2C1=O NUALQIPEWVUAOO-UHFFFAOYSA-N 0.000 claims description 6
- FZCYQIJZJBQHSN-UHFFFAOYSA-N 4-amino-2-[1-(2-methoxybutyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)CC(CC)OC)=O)=O FZCYQIJZJBQHSN-UHFFFAOYSA-N 0.000 claims description 5
- ZKXKEKBZWWFIAI-UHFFFAOYSA-N 4-amino-2-[1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)CC(C)OC)=O)=O ZKXKEKBZWWFIAI-UHFFFAOYSA-N 0.000 claims description 5
- HHDSDZORGYMKCQ-UHFFFAOYSA-N 4-amino-5-methoxy-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1OC)=O)C1C(N(C(CC1)=O)CCOC)=O)=O HHDSDZORGYMKCQ-UHFFFAOYSA-N 0.000 claims description 5
- NSOWCYJODMLUHO-UHFFFAOYSA-N 4-fluoro-2-[1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound FC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)CC(C)OC)=O)=O NSOWCYJODMLUHO-UHFFFAOYSA-N 0.000 claims description 5
- CLIUNIOAUAFMBB-UHFFFAOYSA-N 5-amino-2-[1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC=1C=C2C(N(C(C2=CC=1)=O)C1C(N(C(CC1)=O)CC(C)OC)=O)=O CLIUNIOAUAFMBB-UHFFFAOYSA-N 0.000 claims description 5
- 239000007941 film coated tablet Substances 0.000 claims description 4
- 239000012669 liquid formulation Substances 0.000 claims description 4
- 239000007940 sugar coated tablet Substances 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- DTXOXUHQOZEYQK-UHFFFAOYSA-N 4-amino-2-[1-[2-(dimethylamino)ethyl]-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)CCN(C)C)=O)=O DTXOXUHQOZEYQK-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 20
- 239000000243 solution Substances 0.000 description 107
- 150000001875 compounds Chemical class 0.000 description 95
- 238000006243 chemical reaction Methods 0.000 description 83
- 241001465754 Metazoa Species 0.000 description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 65
- 210000001072 colon Anatomy 0.000 description 65
- 238000002360 preparation method Methods 0.000 description 62
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 49
- 238000004128 high performance liquid chromatography Methods 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 230000000694 effects Effects 0.000 description 36
- 230000002829 reductive effect Effects 0.000 description 35
- 239000012043 crude product Substances 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 241000700159 Rattus Species 0.000 description 29
- 230000005856 abnormality Effects 0.000 description 29
- 230000037396 body weight Effects 0.000 description 28
- 201000010099 disease Diseases 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- 239000003814 drug Substances 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- 0 [1*]C.[3*]O[2*]N1C(=O)CCC(N2C(=O)c3ccccc3C2=O)C1=O Chemical compound [1*]C.[3*]O[2*]N1C(=O)CCC(N2C(=O)c3ccccc3C2=O)C1=O 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- 208000025865 Ulcer Diseases 0.000 description 23
- 229940079593 drug Drugs 0.000 description 23
- 239000012074 organic phase Substances 0.000 description 23
- 231100000397 ulcer Toxicity 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 21
- -1 carrier Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000003921 oil Substances 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 13
- 229940093499 ethyl acetate Drugs 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 11
- 229960001940 sulfasalazine Drugs 0.000 description 11
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 238000003304 gavage Methods 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 9
- XJDKHTYPSNLPTQ-UHFFFAOYSA-N acetic acid 3-amino-1-(2-methoxyethyl)piperidine-2,6-dione Chemical compound CC(O)=O.COCCN1C(=O)CCC(N)C1=O XJDKHTYPSNLPTQ-UHFFFAOYSA-N 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 210000000436 anus Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010023799 Large intestinal ulcer Diseases 0.000 description 4
- 206010061296 Motor dysfunction Diseases 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229940093181 glucose injection Drugs 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229960004963 mesalazine Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WWJAZKZLSDRAIV-UHFFFAOYSA-N 4-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=CC2=C1C(=O)OC2=O WWJAZKZLSDRAIV-UHFFFAOYSA-N 0.000 description 3
- ROFZMKDROVBLNY-UHFFFAOYSA-N 4-nitro-2-benzofuran-1,3-dione Chemical compound [O-][N+](=O)C1=CC=CC2=C1C(=O)OC2=O ROFZMKDROVBLNY-UHFFFAOYSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- YIXAMRRMFCPXNC-JTQLQIEISA-N benzyl n-[(3s)-2,6-dioxooxan-3-yl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)N[C@H]1CCC(=O)OC1=O YIXAMRRMFCPXNC-JTQLQIEISA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011369 resultant mixture Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- CEVMYGZHEJSOHZ-UHFFFAOYSA-N 1-bromo-3-methoxypropane Chemical compound COCCCBr CEVMYGZHEJSOHZ-UHFFFAOYSA-N 0.000 description 2
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- KVRCAGKHAZRSQX-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindole-1,3-dione Chemical compound O=C1C=2C([N+](=O)[O-])=CC=CC=2C(=O)N1C1CCC(=O)NC1=O KVRCAGKHAZRSQX-UHFFFAOYSA-N 0.000 description 2
- SSFKURSGJRBEPO-UHFFFAOYSA-N 2-(3-methyl-2,6-dioxopiperidin-3-yl)-4-nitroisoindole-1,3-dione Chemical compound O=C1C2=CC=CC([N+]([O-])=O)=C2C(=O)N1C1(C)CCC(=O)NC1=O SSFKURSGJRBEPO-UHFFFAOYSA-N 0.000 description 2
- JCYRDRIOFRFFQJ-UHFFFAOYSA-N 2-[1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl]-4-nitroisoindole-1,3-dione Chemical compound [N+](=O)([O-])C1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)CCOCC)=O)=O JCYRDRIOFRFFQJ-UHFFFAOYSA-N 0.000 description 2
- XKGUBRYSPWNTQV-UHFFFAOYSA-N 2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]-4-nitro-5-phenylmethoxyisoindole-1,3-dione Chemical compound [N+](=O)([O-])C1=C2C(N(C(C2=CC=C1OCC1=CC=CC=C1)=O)C1C(N(C(CC1)=O)CCOC)=O)=O XKGUBRYSPWNTQV-UHFFFAOYSA-N 0.000 description 2
- PREMGWIFDVEUDF-UHFFFAOYSA-N 2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]-5-nitroisoindole-1,3-dione Chemical compound [N+](=O)([O-])C=1C=C2C(N(C(C2=CC=1)=O)C1C(N(C(CC1)=O)CCOC)=O)=O PREMGWIFDVEUDF-UHFFFAOYSA-N 0.000 description 2
- AEFPYVAIYDNIMA-UHFFFAOYSA-N 2-[1-(2-methoxyethyl)-3-methyl-2,6-dioxopiperidin-3-yl]-4-nitroisoindole-1,3-dione Chemical compound [N+](=O)([O-])C1=C2C(N(C(C2=CC=C1)=O)C1(C(N(C(CC1)=O)CCOC)=O)C)=O AEFPYVAIYDNIMA-UHFFFAOYSA-N 0.000 description 2
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 2
- XABIMORGEXTPEY-UHFFFAOYSA-N 3-amino-3-methylpiperidine-2,6-dione;hydrochloride Chemical compound Cl.CC1(N)CCC(=O)NC1=O XABIMORGEXTPEY-UHFFFAOYSA-N 0.000 description 2
- KIYSJLJEQIXGCX-UHFFFAOYSA-N 3-nitro-4-phenylmethoxyphthalic acid Chemical compound C(C1=CC=CC=C1)OC=1C(=C(C(C(=O)O)=CC=1)C(=O)O)[N+](=O)[O-] KIYSJLJEQIXGCX-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- YLWQOGNHOPWTJI-UHFFFAOYSA-N 4-amino-2-[1-(3-methoxypropyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1N(CCCOC)C(=O)CCC1N1C(=O)C2=C(N)C=CC=C2C1=O YLWQOGNHOPWTJI-UHFFFAOYSA-N 0.000 description 2
- UISPWTIVPPMAKI-UHFFFAOYSA-N 4-nitro-5-phenylmethoxy-2-benzofuran-1,3-dione Chemical compound C(C1=CC=CC=C1)OC=1C(=C2C(C(=O)OC2=O)=CC=1)[N+](=O)[O-] UISPWTIVPPMAKI-UHFFFAOYSA-N 0.000 description 2
- SMLSULKJKXYXKQ-UHFFFAOYSA-N 5-fluoro-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]-4-nitroisoindole-1,3-dione Chemical compound FC=1C(=C2C(N(C(C2=CC=1)=O)C1C(N(C(CC1)=O)CCOC)=O)=O)[N+](=O)[O-] SMLSULKJKXYXKQ-UHFFFAOYSA-N 0.000 description 2
- MMVIDXVHQANYAE-UHFFFAOYSA-N 5-nitro-2-benzofuran-1,3-dione Chemical compound [O-][N+](=O)C1=CC=C2C(=O)OC(=O)C2=C1 MMVIDXVHQANYAE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- RAOROWOUBLSFOW-UHFFFAOYSA-N C(C)(=O)O.C(C)OCCN1C(C(CCC1=O)N)=O Chemical compound C(C)(=O)O.C(C)OCCN1C(C(CCC1=O)N)=O RAOROWOUBLSFOW-UHFFFAOYSA-N 0.000 description 2
- JKLLITGGRWJARD-UHFFFAOYSA-N COCCCN(C(CCC1N(C(C(C2=C3)=CC=C3[N+]([O-])=O)=O)C2=O)=O)C1=O Chemical compound COCCCN(C(CCC1N(C(C(C2=C3)=CC=C3[N+]([O-])=O)=O)C2=O)=O)C1=O JKLLITGGRWJARD-UHFFFAOYSA-N 0.000 description 2
- AKZFLWSDUAMCNE-UHFFFAOYSA-N COCCCN(C(CCC1N(C(C2=CC=CC([N+]([O-])=O)=C22)=O)C2=O)=O)C1=O Chemical compound COCCCN(C(CCC1N(C(C2=CC=CC([N+]([O-])=O)=C22)=O)C2=O)=O)C1=O AKZFLWSDUAMCNE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 238000001295 Levene's test Methods 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000013029 homogenous suspension Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000010150 least significant difference test Methods 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000011418 maintenance treatment Methods 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- TYVCUTWPNSIHHM-UHFFFAOYSA-N tert-butyl 2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]-5-(methylamino)-1,3-dioxoisoindole-4-carboxylate Chemical compound C(=O)(OC(C)(C)C)C1=C2C(N(C(C2=CC=C1NC)=O)C1C(N(C(CC1)=O)CCOC)=O)=O TYVCUTWPNSIHHM-UHFFFAOYSA-N 0.000 description 2
- SXTNGZNXWKWJIQ-UHFFFAOYSA-N tert-butyl 5-amino-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindole-4-carboxylate Chemical compound C(=O)(OC(C)(C)C)C1=C2C(N(C(C2=CC=C1N)=O)C1C(N(C(CC1)=O)CCOC)=O)=O SXTNGZNXWKWJIQ-UHFFFAOYSA-N 0.000 description 2
- KXLVRTZYNQGCBB-UHFFFAOYSA-N tert-butyl 5-amino-7-hydroxy-2-[1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindole-4-carboxylate Chemical compound C(=O)(OC(C)(C)C)C1=C2C(N(C(C2=C(C=C1N)O)=O)C1C(N(C(CC1)=O)CCOC)=O)=O KXLVRTZYNQGCBB-UHFFFAOYSA-N 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000008791 toxic response Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- GNLJBJNONOOOQC-UHFFFAOYSA-N $l^{3}-carbane;magnesium Chemical compound [Mg]C GNLJBJNONOOOQC-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FEOHYDSNGHIXOM-WLDMJGECSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)-2-methyloxane-2,4,5-triol Chemical compound CC1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO FEOHYDSNGHIXOM-WLDMJGECSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ALOQTNHQNMYBDE-UHFFFAOYSA-N 1-bromo-4-methoxybutane Chemical compound COCCCCBr ALOQTNHQNMYBDE-UHFFFAOYSA-N 0.000 description 1
- MYFKLQFBFSHBPA-UHFFFAOYSA-N 1-chloro-2-methylsulfanylethane Chemical compound CSCCCl MYFKLQFBFSHBPA-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 1
- ZURRKVIQUKNLHF-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[2.2.1]heptane-3-carboxylic acid Chemical compound C1CC2(C)C(C(O)=O)CC1C2(C)C ZURRKVIQUKNLHF-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- OMCXTFVBNCFZMY-UHFFFAOYSA-N 4-fluorophthalic acid Chemical compound OC(=O)C1=CC=C(F)C=C1C(O)=O OMCXTFVBNCFZMY-UHFFFAOYSA-N 0.000 description 1
- CCTOEAMRIIXGDJ-UHFFFAOYSA-N 4-hydroxy-2-benzofuran-1,3-dione Chemical compound OC1=CC=CC2=C1C(=O)OC2=O CCTOEAMRIIXGDJ-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- TWWAWPHAOPTQEU-UHFFFAOYSA-N 4-methyl-2-benzofuran-1,3-dione Chemical compound CC1=CC=CC2=C1C(=O)OC2=O TWWAWPHAOPTQEU-UHFFFAOYSA-N 0.000 description 1
- ZKLQKNDCBYXTBC-UHFFFAOYSA-N 5,6,7,7a-tetrafluoro-3aH-2-benzofuran-1,3-dione Chemical compound FC1=C(F)C(F)=CC2C(=O)OC(=O)C21F ZKLQKNDCBYXTBC-UHFFFAOYSA-N 0.000 description 1
- OOWQMXPXXDBWNV-UHFFFAOYSA-N 5-amino-2-[1-(3-methoxypropyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1N(CCCOC)C(=O)CCC1N1C(=O)C2=CC(N)=CC=C2C1=O OOWQMXPXXDBWNV-UHFFFAOYSA-N 0.000 description 1
- XVMKZAAFVWXIII-UHFFFAOYSA-N 5-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=C2C(=O)OC(=O)C2=C1 XVMKZAAFVWXIII-UHFFFAOYSA-N 0.000 description 1
- LLNIVPQFEHBLOO-UHFFFAOYSA-N 5-fluoro-4-nitro-2-benzofuran-1,3-dione Chemical compound C1=C(F)C([N+](=O)[O-])=C2C(=O)OC(=O)C2=C1 LLNIVPQFEHBLOO-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010060921 Abdominal abscess Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- ZVJIQYQXCWHGIH-UHFFFAOYSA-N CC(NC(C=CC=C1C(N2C(CCC(N3CCCOC)=O)C3=O)=O)=C1C2=O)=O Chemical compound CC(NC(C=CC=C1C(N2C(CCC(N3CCCOC)=O)C3=O)=O)=C1C2=O)=O ZVJIQYQXCWHGIH-UHFFFAOYSA-N 0.000 description 1
- QSFAJPGBTQCDNC-UHFFFAOYSA-N COCCCCN(C(CCC1N(C(C2=CC=CC(N)=C22)=O)C2=O)=O)C1=O Chemical compound COCCCCN(C(CCC1N(C(C2=CC=CC(N)=C22)=O)C2=O)=O)C1=O QSFAJPGBTQCDNC-UHFFFAOYSA-N 0.000 description 1
- BZBJJZIGEDIEIV-UHFFFAOYSA-N COCCCN(C(CCC1N(C(C2=CC=CC(F)=C22)=O)C2=O)=O)C1=O Chemical compound COCCCN(C(CCC1N(C(C2=CC=CC(F)=C22)=O)C2=O)=O)C1=O BZBJJZIGEDIEIV-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010072877 Intestinal fibrosis Diseases 0.000 description 1
- 206010022699 Intestinal stenosis Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 241001510071 Pyrrhocoridae Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940124626 anti-diarrhoeal drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940043232 butyl acetate Drugs 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 201000008909 folic acid deficiency anemia Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000003134 paneth cell Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940096976 rectal foam Drugs 0.000 description 1
- 229940041666 rectal gel Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001180 sulfating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000001575 tandem quadrupole mass spectrometry Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- CYFJIBWZIQDUSZ-UHFFFAOYSA-N thioglycine Chemical compound NCC(S)=O CYFJIBWZIQDUSZ-UHFFFAOYSA-N 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Definitions
- the present disclosure relates to organic chemistry and medicinal chemistry fields.
- Crohn's disease is a chronic inflammatory autoimmune disease of the gastrointestinal tract (GI). Crohn's disease can affect any part of the digestive tract from the mouth to the anus. Under the microscope, Crohn's disease affects the entire intestinal wall (transmural injury). Chronic inflammation can cause fibrosis in the subgroup of patients with Crohn's disease, who have the complications including stenosis and fistula, and possibly need repeated surgery. Crohn's disease is associated with increased risk of gastrointestinal malignant tumour. It is found by the study on Crohn's disease that Crohn's disease is associated with TH1 (type 1 T helper cell) and TH17 (type 17 T helper cell) mediated cellular immunity.
- TH1 type 1 T helper cell
- TH17 type 17 T helper cell
- the clinical manifestations of Crohn's disease are various and include gastrointestinal manifestations, systemic manifestations, parenteral manifestations, and complications.
- Gastrointestinal manifestations mainly include diarrhea, abdominal pain, and bloody stool.
- Systemic manifestations mainly include weight loss, fever, loss of appetite, fatigue, anemia, and the like. Growth retardation is commonly found in adolescent patients.
- Common complications include fistula, abdominal abscess, intestinal stenosis, obstruction and perianal lesions.
- Gastrointestinal bleeding and acute perforation are rare. The long course of disease can lead to cancer. Colonoscopy is generally manifested as segmental and asymmetric various mucosal inflammation, which has the characterized manifestation of non-continuous lesions, longitudinal ulcers and pebble-like appearance.
- the histopathological changes of Crohn's disease mucosal biopsy samples include: (1) focal discontinuous infiltration of intrinsic membrane inflammatory cells; (2) fissuring ulcers; (3) aphthous ulcers; (4) abnormal crypt structure, glandular hyperplasia, individual crypt abscess, non-obvious reduction of mucus secretion, visible pyloric metaplasia or Paneth cell metaplasia; (5) non-cheese-like necrotic granuloma; (6) chronic inflammatory cell infiltration of lymphocytes and plasma cells, in which the inflammation at the bottom of lamina limba and submucosal layer is severe, and formation of lymph follicle is common; and (7) submucosal lymphatic dilatation; and (8) ganglion cell proliferation and/or ganglion inflammation.
- Mildly active Crohn's disease is treated mainly with 5-aminosalicylic acids and budesonide. If the above treatment is ineffective, Crohn's disease is considered as moderately active. Moderately active Crohn's disease is preferably treated with hormone (such as dexamethasone). If the above treatment is ineffective or becomes dependent, combination with thioglycine or methotrexate will be considered. TNF- ⁇ monoclonal antibody can be used if the above hormone therapy and immunotherapy are ineffective or intolerable. Severely active Crohn's disease is treated mainly with systemic hormones, TNF- ⁇ monoclonal antibodies and surgery. Drugs for maintenance treatment for Crohn's disease in remission include 5-aminosalicylic acids, thioglycines and TNF- ⁇ monoclonal antibodies.
- 5-aminosalicylic acid drugs such as sulfasalazine and mesalazine
- sulfasalazine and mesalazine 5-aminosalicylic acid drugs
- budesonide or azathiopurine can also be used, but only in a short term.
- Monoclonal antibody drugs such as infliximab and adalimumab
- infliximab may cause high blood pressure, chills, rash, fever, headache, eczema and so on.
- infliximab is a chimeric antibody, it is possible to show antigenicity and sometimes cause acute hypersensitivity.
- TNF- ⁇ inhibitors such as lenalidomide and thalidomide have been shown to be not effective in the treatment of Crohn's disease (C. Yang et, Aliment Pharmacol Ther 2015; 41:1079-7093.).
- Crohn's disease is a chronic disease that requires a longer duration of drugs.
- the above data show that there is no drug for long-term effective treatment of Crohn's disease, especially drug by oral administration. Therefore, there is a need for developing better target therapy with optimized chronic use for Crohn's disease, or drugs with better effectiveness or better safety.
- DNBS Dinitrobenzene sulfonic acid
- TNBS trinitrobenzene sulfonic acid
- TNF- ⁇ inhibitors such as lenalidomide and thalidomide have been shown to be not effective in the treatment of Crohn's disease (C. Yang et, Aliment Pharmacol Ther 2015; 41:1079-7093.).
- some embodiments disclose a piperidine-2,6-dione derivative of formula (I) and pharmaceutically acceptable salts thereof:
- R 1 represents one or more substituents selected from the group consisting of H, halogen, —OH, —C 1-4 alkyl, —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 and —NHCOC 1-4 alkyl;
- R 2 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 3 represents —H or —C 1-4 alkyl.
- R 4 represents one or more substituents selected from the group consisting of H, halogen, —C 1-4 alkyl, —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 and —NHCOC 1-4 alkyl;
- R 5 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 6 represents —S—, —SO—, —SO 2 —, —NH— or —N(C 1-4 alkyl)-;
- R 7 represents —H or —C 1-4 alkyl.
- R 8 represents one or more substituents selected from the group consisting of H, halogen, —C 1-4 alkyl, —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 and —NHCOC 1-4 alkyl;
- R 9 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 10 represents —O—, —S—, —SO—, —SO 2 —, —NH— or —N(C 1-4 alkyl)-;
- R 11 represents —H or —C 1-4 alkyl
- R 12 represents halogen or —C 1-4 alkyl.
- some embodiments disclose a piperidine-2,6-dione derivative and pharmaceutically acceptable salts thereof, which are selected from the group consisting of:
- some embodiments disclose a pharmaceutical composition
- a pharmaceutical composition comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, and a pharmaceutically acceptable carrier, diluent or excipient.
- some embodiments disclose a method for treating Crohn's disease, comprising administering a therapeutically effective amount of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, or a therapeutically effective amount of the pharmaceutical composition as disclosed herein to a subject in need thereof.
- some embodiments disclose the piperidine-2,6-dione derivative and pharmaceutically acceptable salts thereof of as disclosed herein for treating Crohn's disease.
- some embodiments disclose a pharmaceutical composition for treating Crohn's disease, comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, and a pharmaceutically acceptable carrier, diluent or excipient.
- Crohn's disease can be mild Crohn's disease, moderate Crohn's disease, or severe Crohn's disease. According to the activity of disease, Crohn's disease can be divided into active Crohn's disease or Crohn's disease in remission.
- the goal of treatment for Crohn's disease is to induce active Crohn's disease to enter the remission (i.e, induction of remission) and/or to maintain the disease in remission (i.e., maintenance of remission).
- CDAI Crohn's disease activity index
- the patient's disease was scored according to the Best CDAI calculation as described above. After scoring, the clinical remission corresponds to Crohn's disease in remission of the present disclosure, mild activity corresponds to mild Crohn's disease of the present disclosure, moderate activity corresponds to moderate Crohn's disease of the present disclosure, and severe activity corresponds to severe Crohn's disease of the present disclosure.
- C 1 -C 4 alkyl describes an alkyl group, as defined below, having a total of 1 to 4 carbon atoms
- C 3 -C 10 cycloalkyl describes a cycloaklyl group, as defined below, having a total of 3 to 10 carbon atoms.
- the total number of carbon atoms in the shorthand notation does not include the carbons that may exist in the substituents of the groups described.
- mammals means animals including, for example, dogs, cats, cows, sheep, horses, and humans. In some embodiments, mammals include humans.
- patient means an animal, such as a human, a companion animal, such as a dog, cat and horse, and livestock, such as cattle, swine and sheep.
- livestock such as cattle, swine and sheep.
- patients are mammals, including both males and females.
- patients are humans.
- pharmaceutically acceptable means the carrier, vehicle, diluent, excipient and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.
- “Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isosmotic agent, solvent, or emulsifier, etc, which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or animals and have no side effects on preparing a pharmaceutical composition.
- “Pharmaceutically acceptable salts” include both “pharmaceutically acceptable acid addition salts” and “pharmaceutically acceptable base addition salts”.
- “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but not limited to hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphanic acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid,
- “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited, to sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminium salts and the like. In some embodiments, inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and s basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucosamine, theobromine, triethanolamine, trometamol, purine, piperazine, piperidine, N-ethyl piperidine, polyamine resins and the like.
- organic bases are isopropylamine, diethy
- a solvent or a solvent mixture refers to any and all solvents
- a solvent or a solvent mixture is organic solvents and water, which include, but are not limited to, water, methanol, ethanol, 2-propanol, n-butanol, iso-butanol, acetone, methylethylketone, ethylacetate, 1,4-dioxane, diethylether, MTBE, THF, acetonitrile, dichloromethane, chloroform, DMF, cyclohexane, cyclopentane, n-hexane, n-heptane, n-pentane, toluene, o-xylene, p-xylene, DMSO, pyridine, acetic acid, anisole, butylacetate, cumene, ethylformate, formic acid, iso-butylacetate, iso-propylacetate,
- a “pharmaceutical composition” refers to a formulation of a compound of the present disclosure and a medium generally acceptable in the art for the delivery of the biologically active compound to mammals, e.g., humans.
- a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.
- “Therapeutically effective amount” refers to an amount of a compound or combination of compounds that ameliorates, attenuates or eliminates a particular disease or condition or a symptom of a particular disease or condition, or prevents or delays the onset of a particular disease or condition or a symptom of a particular disease or condition.
- the amount of a compound of the present disclosure which constitutes a “therapeutically effective amount” will vary depending on the compound, the condition and its severity, and the age of the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
- Treating” or “treatment” as used herein covers the treatment of the disease or condition of interest in a mammal, such as a human, having the disease or disorder of interest, and includes:
- the terms “disease” and “condition” may be used interchangeably or may be different in that the particular malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians.
- the compounds of the present disclosure or their pharmaceutically acceptable salt may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereoisomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or (D)- or (L)- for amino acids.
- the present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms.
- Optically active (+) and ( ⁇ ), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as HPLC using a chiral column.
- the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
- stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
- the present disclosure contemplates various stereoisomers and mixtures thereof.
- substitution site of R 1 in formula (I) can be one of the sites numbered as 4, 5, 6 and 7 or a combination of several sites numbered as 4, 5, 6 and 7.
- substitution site of R 4 in formula (II) can be one of the sites numbered as 4, 5, 6 and 7 or a combination of several sites numbered as 4, 5, 6 and 7.
- substitution site of R 8 in formula (III) can be one of the sites numbered as 4, 5, 6 and 7 or a combination of several sites numbered as 4, 5, 6 and 7.
- some embodiments disclose a piperidine-2,6-dione derivative of formula I) and pharmaceutically acceptable salts thereof:
- R 1 represents one or more substituents selected from the group consisting of H, halogen, —OH, —C 1-4 alkyl, —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 and —NHCOC 1-4 alkyl;
- R 2 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 3 represents —H or —C 1-4 alkyl.
- R 1 represents one or more substituents selected from the group consisting of —H, —F, —Cl, —Br, —OH, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —NHCH 3 , —NH 2 , —NHCH 2 CH 3 , —N(CH 3 ) 2 , —N(CH 2 CH 3 ) 2 , —NHCOCH 3 and —NHCOCH 2 CH 3 ;
- R 2 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 3 represents —H, —CH 3 or —CH 2 CH 3 .
- R 1 represents one or more substituents selected from the group consisting of —H, —F, —OH, —CH 3 , —NHCH 3 , —N(CH 3 ) 2 , —NHCOCH 3 and —NH 2 ;
- R 2 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 3 represents —H, —CH 3 or —CH 2 CH 3 .
- piperidine-2,6-dione derivatives of formula (I) and pharmaceutically acceptable salts thereof which are selected from the group consisting of:
- some embodiments disclose a piperidine-2,6-dione derivative of formula (II) and pharmaceutically acceptable salts thereof:
- R 4 represents one or more substituents selected from the group consisting of H, halogen, —C 1-4 alkyl, —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 and —NHCOC 1-4 alkyl;
- R 5 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 6 represents —S—, —SO—, —SO 2 —, —NH— or —N(C 1-4 alkyl)-;
- R 7 represents —H or —C 1-4 alkyl.
- R 4 represents one or more substituents selected from the group consisting of —H, —F, —Cl, —Br, —OH, —CH 3 , —NHCH 3 , —NHCH 2 CH 3 , —NH 2 , —N(CH 3 ) 2 , —N(CH 2 CH 3 ) 2 , —NHCOCH 3 and —NHCOCH 2 CH 3 ;
- R 5 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 6 represents —S—, —SO—, —SO 2 —, —NH— or —N(CH 3 )—;
- R 7 represents —H, —CH 3 or —CH 2 CH 3 .
- R 4 represents —NH 2 or —NHCOCH 3 ;
- R 5 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 6 represents —S—, —SO—, —SO 2 —, —NH— or —N(CH 3 )—;
- R 7 represents —H, —CH 3 or —CH 2 CH 3 .
- R 8 represents one or more substituents selected from the group consisting of H, halogen, —C 1-4 alkyl, —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 and —NHCOC 1-4 alkyl;
- R 9 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 10 represents —O—, —S—, —SO—, —SO 2 —, —NH— or —N(C 1-4 alkyl)-;
- R 11 represents —H or —C 1-4 alkyl
- R 12 represents halogen or —C 1-4 alkyl.
- R 8 represents one or more substituents selected from the group consisting of —H, —F, —Cl, —Br, —OH, —CH 3 , —NHCH 3 , —NHCH 2 CH 3 , —NH 2 , —N(CH 3 ) 2 , —N(CH 2 CH 3 ) 2 , —NHCOCH 3 and —NHCOCH 2 CH 3 ;
- R 9 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 10 represents —O—, —S—, —SO—, —SO 2 —, —NH— or —N(CH 3 )—;
- R 11 represents —H, —CH 3 or —CH 2 CH 3 ;
- R 12 represents halogen or —C 1-4 alkyl.
- R 8 represents —NH 2 or —NHCOCH 3 ;
- R 9 represents —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 —;
- R 10 represents —O—, —S—, —SO—, —SO 2 —, —NH— or —N(CH 3 )—;
- R 11 represents —H, —CH 3 or —CH 2 CH 3 ;
- R 12 represents halogen or —C 1-4 alkyl.
- piperidine-2,6-dione derivatives and pharmaceutically acceptable salts thereof which are selected from the group consisting of:
- some embodiments disclose a pharmaceutical composition
- a pharmaceutical composition comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, and a pharmaceutically acceptable carrier, diluent or excipient.
- some embodiments disclose a method for treating Crohn's disease, comprising administering a therapeutically effective amount of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, or a therapeutically effective amount of the pharmaceutical composition as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, comprising administering 1 mg-10 g of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, comprising administering 10 mg-3000 mg of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, comprising administering 100 mg-1000 mg of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, comprising administering 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg or 1000 mg of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, wherein the Crohn's disease is mild Crohn's disease, moderate Crohn's disease, severe Crohn's disease or Crohn's disease in remission.
- Some embodiments disclose a method for treating Crohn's disease, wherein the subject in need thereof is a mammal.
- Some embodiments disclose a method for treating Crohn's disease, wherein the subject in need thereof is human.
- Some embodiments disclose of a method of maintenance treatment of Crohn's disease, comprising administering a therapeutically effective amount of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, or a therapeutically effective amount of the pharmaceutical composition as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, wherein the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, or the pharmaceutical composition comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein is administered orally.
- Some embodiments disclose a method for treating Crohn's disease, wherein the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, or the pharmaceutical composition comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein is administered orally in a solid or liquid formulation.
- Exemplary examples of the solid formulation that can be used in the method for treating Crohn's disease as disclosed herein comprise, but are not limited to, a tablet, capsule and sugar-coated pill.
- Exemplary examples of the tablet that can be used in the method for treating Crohn's disease as disclosed herein comprise, but are not limited to, a plain tablet, sugar-coated tablet and film-coated tablet.
- Exemplary examples of the liquid formulation that can be used in the method for treating Crohn's disease as disclosed herein comprise, but are not limited to, a solution and suspension.
- some embodiments disclose a piperidine-2,6-dione derivative and pharmaceutically acceptable salts thereof for treating Crohn's disease.
- some embodiments disclose a pharmaceutical composition for treating Crohn's disease, comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, and a pharmaceutically acceptable carrier, diluent or excipient.
- the piperidine-2,6-dione derivatives as disclosed herein have good therapeutical effects.
- the piperidine-2,6-dione derivatives as disclosed herein have better tolerance.
- Some embodiments disclose a pharmaceutical composition
- a pharmaceutical composition comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, and a pharmaceutically acceptable carrier, diluent or excipient.
- the route of administration of the piperidine-2,6-dione derivatives as disclosed herein to the mammals can be non-parenteral route.
- the route of administration of the piperidine-2,6-dione derivatives as disclosed herein to the mammals can be oral route.
- the route of administration of the piperidine-2,6-dione derivatives as disclosed herein to the mammals can be intrarectal route.
- the piperidine-2,6-dione derivatives as described herein may be obtained in any suitable form such as tablet, capsule, powder, oral solution, suspension, rectal gel, rectal foam, rectal enema or suppository and the like.
- exemplary examples of tablets comprise, but are not limited to, plain tablets, sugar-coated tablets and film-coated tablets.
- a pharmaceutically acceptable carrier that can be used in the pharmaceutical composition of the present disclosure include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isosmotic agent, solvent or emulsifier, which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or animals.
- Acceptable carriers or diluents for therapeutic use are well-known in the art, and are described, for example, in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, Pa. (1990), which is incorporated herein by reference in its entirety.
- compositions of the present disclosure may be administered by any means that achieve their intended purpose.
- administration may be by oral, parenteral, topical, enteral, intravenous, intramuscular, inhalant, nasal, intraarticular, intraspinal, transtracheal, transocular, subcutaneous, intraperitoneal, transdermal, or buccal routes.
- the route of administration can be non-parenteral route, oral route and intrarectal route.
- the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- Suitable dosage forms include, but are not limited to capsules, tablets, pellets, dragees, semi-solids, powders, granules, suppositories, ointments, creams, lotions, inhalants, injections, cataplasms, gels, tapes, eye drops, solution, syrups, aerosols, suspension, emulsion, which can be produced according to methods known in the art.
- Particularly suitable for oral use are ordinary tablets (plain tablets), sugar-coated tablet, film-coated tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops, suitable for rectal use are suppositories, suitable for parenteral use are solutions, or oil-based or aqueous solutions, furthermore suspensions, emulsions or implants, and suitable for topical use are ointments, creams or powders.
- the compounds of the present disclosure may also be lyophilised and the resultant lyophilisates used, for example, for the preparation of injection preparations.
- the preparations indicated may be sterilised and/or comprise assistants, such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, dyes, flavours and/or a plurality of further active ingredients, for example one or more vitamins.
- assistants such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, dyes, flavours and/or a plurality of further active ingredients, for example one or more vitamins.
- a pharmaceutical composition of the present disclosure is formulated as tablet, solution, granule, patch, ointment, capsule, aerosol or suppository administered via parenteral, transdermal, mucosa, nasal, buccal, sublingual or oral route.
- Preservatives may be provided in the pharmaceutical composition.
- sodium benzoate, ascorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives.
- antioxidants and suspending agents may be used.
- alcohols, esters, sulfating aliphatic alcohols, and the like may be used as surfactants; sucrose, glucose, lactose, starch, crystalline cellulose, mannitol, light anhydrous silicate, magnesium aluminate, methyl magnesium silicate aluminate, synthetic aluminum silicate, calcium carbonate, calcium bicarbonate, calcium hydrogenphosphate, calcium hydroxymethyl cellulose and the like may be used as excipients; magnesium stearate, tale, hardened oil may be used as smoothing agents; coconut oil, olive oil, sesame oil, peanut oil, soybean may be used as suspending agents or lubricants; cellulose acetate phthalate as a derivative of a carbohydrate such as cellulose or sugar, or methylacetate-methacrylate copolymer as a derivative of polyethylene may be used as suspending agents; and plasticizers such as ester phthalates and the like may be used as suspending agents.
- Suitable routes of administration may, for example, include oral, rectal, transmucosal, topical, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal or intraocular injections.
- the compound can be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills, transdermal (including electromigrating) patches, and the like for prolonged and/or timed, pulsed administration at a predetermined rate.
- compositions of the present disclosure may be manufacture in manner that is itself known, for example, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or tabletting processes.
- compositions for use in accordance with the present disclosure thus may be formulated by a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing the active compounds into preparation which can be used pharmaceutically. Proper formulation is dependent on the route of administration chosen. Any of the well-known techniques, carriers and excipients may be used as suitable and as understood in the art.
- Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
- Suitable excipients are, for example, water, saline, glucose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, and the like.
- the injectable pharmaceutical compositions may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like.
- Physiologically compatible buffers include, but are not limited to, Hank's solution, Ringer's solution or physiological saline buffer. If desired, absorption enhancing preparations (such as liposomes) may be used.
- the compound can be formulated readily by combining the active compound with pharmaceutically acceptable carriers well known in the art.
- Such carriers enable the compound of the disclosure to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, ointments, suspensions, and the like, for oral ingestion by a patient to be treated.
- Pharmaceutical preparation for oral use can be obtained by combining the active compound with solid excipient, optionally grinding a resultant mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, including lactose, saccharose, mannitol or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
- disintegrating agents may be added, such as the crosslinked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings.
- concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solution, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added into the tablets or dagree coatings for identification or to characterizing different combinations of active compound doses.
- concentrated sugar solutions may be used, which may optionally contain gum arabic, tale, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solution, and suitable organic solvents or solvent mixtures.
- compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
- the push-fit capsules can contain active ingredients in admixture with filler such as sugar, binders such as starches, and/or lubricants such as tale or magnesium stearate and, optionally, stabilizers.
- the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oil, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
- the pharmaceutical composition of the present disclosure may comprise 0.1%-95% of the piperidine-2,6-dione derivatives as disclosed herein.
- the pharmaceutical composition of the present disclosure may comprise 1%-70% of the piperidine-2,6-dione derivatives as disclosed herein.
- composition or formulation to be administered may comprise some amount of the piperidine-2,6-dione derivatives as disclosed herein, which is effective to treat the disease/condition of a study subject to be treated.
- At least one of the compounds of the present disclosure or the pharmaceutical compositions comprising at least one of the compounds of the present disclosure may be administered to the patient by any suitable means and/or by any means that topically delivers the compounds of the present disclosure.
- methods of administration include, among others, (a) administration though oral pathways, which administration includes administration in capsule, tablet, granule, spray, syrup, or other such forms; (b) administration through non-oral pathways such as rectal, vaginal, intraurethral, intraocular, intranasal, or intrarticular, which administration includes administration as an aqueous suspension, an oily preparation or the like or as a drip, spray, suppository, salve, ointment or the like; (c) administration via injection, subcutaneously, intraperitoneally, intravenously, intramuscularly, intradermally, intraorbitally, intracapsularly, intraspinally, intrasternally, or the like, including infusion pump delivery; (d) administration locally such as by injection directly in the renal or cardiac area,
- the most suitable route depends on the nature and severity of the condition to be treated.
- a person having ordinary skill in the art also knows determination of methods of administration (buccal, intravenous, inhalation subcutaneous, rectal and the like), dosage form, suitable pharmaceutical excipients and other events regarding delivering the compound to a subject in need thereof.
- compositions suitable for administration include compositions where the active ingredients are contained in an amount effective to achieve its intended purpose.
- the therapeutically effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including human, being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed.
- the determination of effective dosage levels can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.
- dosages may range broadly, depending upon the desired affects and the therapeutic indication. Typically, dosages may be between about 10 microgram/kg and 1000 mg/kg body weight, in some embodiments, between about 100 microgram/kg and 300 mg/kg body weight. Alternatively dosages may be based and calculated upon the surface area of the patient, as understood by those of skill in the art.
- the exact formulation, route of administration and dosage for the pharmaceutical compositions of the present disclosure can be chosen by the individual physician in view of the patient's condition.
- the dose range of the composition administered to the patient can be from about 0.5 to 1000 mg/kg of the patient's body weight.
- the dosage may be a single one or a series of two or more given in the course of one or more days, as is needed by the patient.
- human dosages for compounds have been established for at least some condition, the present disclosure will use those same dosages, or dosages that are between about 0.1% and 500%, in some embodiments, between about 25% and 250% of the established human dosage.
- a suitable human dosage can be inferred from ED 50 or ID 50 values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.
- the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity or organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity).
- the magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
- the daily dosage regimen for an adult human patient may be, for example, an oral dose of between 0.1 mg and 2000 mg of each active ingredient, in some embodiments, between 1 mg and 2000 mg, e.g. 5 to 1500 mg.
- an intravenous, subcutaneous, or intramuscular dose of each active ingredient of between 0.01 mg and 1000 mg, in some embodiments, between 0.1 mg and 1000 mg, e.g. 1 to 800 mg is used.
- dosages may be calculated as the free base.
- the composition is administered 1 to 4 times per day.
- compositions of the disclosure may be administered by continuous intravenous infusion, in some embodiments, at a dose of each active ingredient up to 2000 mg per day.
- each active ingredient up to 2000 mg per day.
- the compounds disclosed herein in certain situations it may be necessary to administer the compounds disclosed herein in amounts that exceed, or even far exceed, the above-stated dosage range in order to effectively and aggressively treat particularly aggressive diseases or infections.
- the compounds will be administered for a period of continuous therapy, for example for a week or more, or for months or years.
- Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC).
- MEC minimal effective concentration
- the MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.
- Dosage intervals can also be determined using MEC value.
- Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, in some embodiments, between 30-90% and in some embodiments, between 50-90%.
- the effective local concentration of the drug may not be related to plasma concentration.
- composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
- the toxicology of a particular compound, or of a subset of the compounds, sharing certain chemical moieties may be established by determining in vitro toxicity towards a cell line, such as a mammalian, and in some embodiments, human, cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans.
- a cell line such as a mammalian, and in some embodiments, human, cell line.
- the results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans.
- the toxicity of particular compounds in an animal model such as mice, rats, rabbits, or monkeys, may be determined using known methods.
- the efficacy of a particular compound may be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials.
- compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack may for example comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- the pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert.
- Compositions comprising a compound of the disclosure formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- LPS lipopolysaccharide
- PBS phosphate buffered saline
- PBST 0.05% of Tween-20 in phosphate buffered saline
- HRP horseradish peroxidase
- TMB 3,3′,5,5′-tetramethylbenzidine
- DSS dextra sulfate sodium
- 5-ASA 5-aminosalicylic acid
- CMC-Na sodium carboxymethyl cellulose
- DNBS dinitrobenzenesulfonic acid
- 1% CMC-Na 1% (weight/volume) of CMC-Na in water
- DSS 1.6% (weight/volume) of DSS in water
- DSS 0.9% (weight/volume) of DSS in water
- mg/Kg milligram/kilogram
- mg/Kg/d milligram/kilogram/day
- ml/Kg milliliter/kilogram
- Mean ⁇ SD Mean ⁇ standard deviation
- cm 2 square centimeter
- MPO myeloperoxidase
- ⁇ L microliter
- nm nanometer
- OD value optical density value
- the Chinese patent No. ZL200510013292.3 discloses the preparation process of 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione, which is incorporated herein by reference in its entirety.
- the aqueous phase was back-extracted with ethyl acetate four times.
- the organic phases were combined.
- the combined organic phase was washed with saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and filtered.
- the organic phase was concentrated under reduced pressure to give a crude product.
- the crude product was purified with silica gel column chromatography to give the title compound as a yellow solid (2.0 g) (HPLC purity: 95.53%). Yield: 49.2%.
- 3-amino-3-methylpiperidin-2,6-dione hydrochloride was prepared in accordance with PCT Int. Appl., 2006081251, 3 Aug. 2006.
- N-((benzyloxy)carbonyl)-glutamic anhydride was prepared in accordance with Archives of Pharmacal Research, 31(7), 834-837; 2008.
- N,N′-carbonyldiiazole (23.4 g) was added into the above reaction solution in batch. The resultant solution was stirred at the room temperature over 72 hours until the reaction was complete. The solution was concentrated under reduced pressure. To the concentrate was added dichloromethane (500 mL). The resultant solution was washed with 1 N hydrochloric acid (250 mL), saturated aqueous solution of sodium bicarbonate (250 mL) and saturated aqueous solution of sodium chloride (250 mL).
- N-((benzyloxy)carbonyl)-glutamic anhydride was used to prepare 1-(2-ethoxyethyl)-3-benzyloxyamido-2,6-piperidinedione as a brown oily crude product (17.2 g).
- reaction solution was poured into saturated aqueous solution of ammonium chloride (400 mL).
- the resultant solution was extracted with ethyl acetate (200 mL ⁇ 3).
- the organic phases were combined.
- the combined organic phase was dried over anhydrous sodium sulfate and filtered.
- the filtrate was concentrated.
- the residue was separated with column chromatography to give 4-nitro-2-(1-(3-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione (1.211 g). Yield: 32.3%.
- the Chinese patent No. ZL200510013292.3 discloses the preparation process of 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione, which is incorporated herein by reference in its entirety.
- Wistar rats male, body weight of 100-120 g.
- mice 90 male Wistar rats were fasted for 40 hours. A 5% glucose injection was administered subcutaneously during fasting. 60 rats with normal conditions and moderate body weight were selected from the fasting rats. The animals were randomly divided into 6 groups according to the body weight: normal control group, model control group, sulfasalazine group (300 mg/Kg), and the compound in Example 27 groups consisting of 5, 15 and 30 mg/Kg dose groups. There were 10 rats in each group. The animals were anesthetized with ether. A specially made gavage device (made by a rat gavage device having the diameter of 2 mm, which was nested on a mouse gavage device having the diameter of 1 mm) was slowly inserted into the enteric cavity at 8 cm from the anus.
- a specially made gavage device made by a rat gavage device having the diameter of 2 mm, which was nested on a mouse gavage device having the diameter of 1 mm
- the model control group, the sulfasalazine group and the compound in Example 27 groups were administered with 0.5 mL of 50 mg/mL DNBS in 30% ethanol solution.
- the normal control group was administered with 0.5 mL of 30% ethanol solution.
- the animals were inverted in anesthesia for 15 minutes after the gavage device was removed.
- the day when the model was prepared was the first day of the experiment.
- the corresponding drug or the corresponding volume of 1% CMC-Na was administered once per day.
- the body weights were recorded and the stool characteristics were scored.
- colon tissues were taken from the animals to observe the results of each index.
- Example 27 The compound in Example 27 and sulfasalazine: Preparation Method: Suspended with 1% CMC-Na, and prepared when it was needed.
- the frozen tissue was ground into powder in liquid nitrogen. An appropriate amount of the powder was weighed and was added into 50 mM potassium phosphate solution (containing 0.5% cetyltrimethylammonium bromide) to give a 25 mg/mL solution. The resultant solution was homogenized by an electric homogenizer. 1 mL of suspension was centrifuged to give a supernatant. 7 ⁇ L of the supernatant was added into a 96-well plate and 200 ⁇ L of o-dianisidine mixture (containing 0.167 mg/mL o-dianisidine and 0.0006% H 2 O 2 potassium phosphate buffer). OD values of the resultant solution at 0, 30, 60, and 90 s were detected at 450 nm of the microplate reader.
- results of colonic tissue-related indexes showed that compared with the normal control group, the colon of the model control group was significantly shortened, the colon tissue was abnormally proliferated and the colon weight was increased. At the same time, the MPO activity of colon tissue was significantly increased, the colon had a larger area of ulcer injury. Sulfasalazine as positive drug at the dose of 300 mg/Kg reduced the colon abnormal proliferation and reduced the colon weight, and had some improvement on colonic ulcers with the reduction of the ulcer area by 60%.
- the compound in Example 27 at the dose of 5 mg/Kg, 15 mg/Kg and 30 mg/Kg reduced the adhesion degree of colons, reduced the weight of colon tissue and the ulcer degree, and reduced the MPO activity of colon tissue, and thus showed a certain dose effect and a good therapeutic effect without the weight loss of animals.
- the compound in Example 27 at the dose of 30 mg/Kg reduced the ulcer degree of colon with a reduction of the ulcer area by about 80%, while the MPO activity of colon tissue was significantly reduced (P ⁇ 0.05), of which the therapeutic effects are better than those of sulfasalazine as positive drug at the dose of 300 mg/Kg.
- mice 110 male Wistar rats were fasted for 40 hours.
- a 5% glucose injection (10 mL/Kg) was administered subcutaneously during fasting.
- 48 rats with normal conditions and moderate body weight were selected from the fasting rats.
- the animals were randomly divided into 5 groups according to the body weight: normal control group, model control group, sulfasalazine group (300 mg/Kg), dexamethasone group (0.1 mg/Kg), the compound in Example 26 group (30 mg/kg) and the compound in Example 27 group (30 mg/kg), with 8 rats in each group.
- the animals were anesthetized with isoflurane.
- a specially made gavage device (made by a rat gavage device having the diameter of 2 mm, which was nested on a mouse gavage device having the diameter of 1 mm) was slowly inserted into the enteric cavity at 8 cm from the anus.
- the model control group, the compound in Example 26 group and the compound in Example 27 group were administered with 0.5 mL of 50 mg/mL DNBS in 30% ethanol solution.
- the normal control group was administered with 0.5 mL of 30% ethanol solution.
- the animals were inverted in anesthesia for 15 minutes after the gavage device was removed.
- the day when the model was prepared was the first day of the experiment. After 4 hours of DNBS induction, the corresponding drug or the corresponding volume of 1% CMC-Na was administered once per day.
- the animals were euthanized to observe the results of each index so as to score the colon adhesion degree, measure the length of colon and ulcer area, weigh colon and calculate the colon weight to length ratio.
- Example 26 The compound in Example 26 and Example 27, sulfasalazine and dexamethasone: Preparation Method: Suspended with 1% CMC-Na, and prepared when it was needed.
- Levene's Test for homogeneity of data was performed with Spss. Where the data were homogeneous (P>0.05), one-way ANOVA LSD test was performed. Where the analysis of variance was significant (P ⁇ 0.05), Dunnett's multiple comparison (parameter method) was performed. Where the results of Levene's Test were significant (P ⁇ 0.05), Kruskal-Wallis nonparametric test was performed. Where the results of Kruskal-Wallis nonparametric test were significant (P ⁇ 0.05), Mann-Whitney U test was performed for pairwise comparison.
- Colon indexes showed that the area of colonic ulcer and the weight of colon of model control group were significantly higher than those of normal control group (P ⁇ 0.05), and the colon was significantly shortened. Compared with model control group, there was significant reduction in the area of colonic ulcer in each administration group (P ⁇ 0.05).
- the animals were anesthetized with ether after 40 hours fasting. A specially made gavage device was slowly inserted into the enteric cavity at 8 cm from the anus.
- the model control group and each test group were administered with 0.5 mL of 50 mg/mL DNBS in 30% ethanol solution.
- the normal control group was administered with 0.5 mL of 30% ethanol solution.
- the animals were inverted in anesthesia for 15 minutes. The day when the model was prepared was day 0 of the experiment. After 4 hours of DNBS induction, the corresponding drug or the corresponding volume of 1% CMC-Na was administered once per day. On day 7 of the experiment, the animals were euthanized to score the colon adhesion degree, measure the length of colon and ulcer area, weigh colon and calculate the colon weight to length ratio.
- the pathological changes of the colon (adhesion, hyperplasia and ulcer) in the animals can be effectively relieved by the treatment in each experimental group.
- the animals were anesthetized with ether after 72 hours fasting. A specially made gavage device was slowly inserted into the enteric cavity at 8 cm from the anus.
- the model control group and each test group were administered with 0.5 mL of 50 mg/mL DNBS in 30% ethanol solution.
- the normal control group was administered with 0.5 mL of 30% ethanol solution.
- the animals were inverted in anesthesia for 15 minutes. The day when the model was prepared was day 0 of the experiment. After 4 hours of DNBS induction, the corresponding drug or the corresponding volume of 1% CMC-Na was administered once per day. On day 7 of the experiment, the animals were euthanized to score the colon adhesion degree, measure the length of colon and ulcer area, weigh colon and calculate the colon weight to length ratio.
- Example 13 TABLE 13 Grouped Table DNBS Clysis Administration Number DNBS Concentration Volume Administration Dose Administration of Groups Solvent (mg/ml) (ml/rat) Route (mg/Kg) Regimen Animals Normal 30% 0 0.5 — — — 8 Control Group ethanol Model Control 50 0.5 i.g — qd ⁇ 7 Group Example 27 30 Example 8 Example 14 Example 24 Example 5 Example 23 Example 10 Example 2 Example 12 Note: The drug in the experiment was suspended with 1% CMC-Na to prepare a 3 mg/mL of homogenous suspension. The administration volume was 10 mL/Kg. i.g: intragastric administration. qd ⁇ 7: once per day, a total of 7 times.
- the pathological changes of the colon (adhesion, hyperplasia and ulcer) in the animals can be effectively relieved by the treatment in each experimental group.
- mice The mice were fasted one day before the experiment. On the day of the experiment, 6 mice (ICR mice, body weight of 19-21 g, three females and three males) were selected in each experiment group. First of all, one female and one male were selected to orally give 1000 mg/Kg, and observed for 5-10 minutes. If there were no obvious side effects, the remaining 4 animals were orally given the same dose, and observed for 10-15 minutes. If no animal died, the animals were placed in a box to balancedly feed for 7 days. The state was observed and the body weight was recorded daily. The animal grouping plan and the initial dose of the drug were shown in the table below:
- Nervous system response tremor, spasm, convulsion, ataxia, posture abnormality, etc.
- Autonomic nerve exophthalmos, salivation, tears, urination (hematuria), diarrhea, piloerection, breathing, etc.
- Example 11 Male Abnormality was not observed in 7 days of the test Female Decrease of activity was observed in one animal after administration but activity was recovered within 3 minutes. Abnormality was not observed in all the animals from day 2 to 7.
- Example 20 Male Decrease of activity was observed in one animal 11 minutes after administration but activity was recovered later. Abnormality was not observed in all the animals from day 2 to 7.
- Example 17 Male Motor dysfunction in two animals was observed 30 minutes after administration and function was recovered later. Abnormality was not observed in all the animals from day 2 to 7.
- Female Motor dysfunction in one animal was observed 10 minutes after administration and function was recovered later.
- the body weight of the animals in each group had a trend of increase with slight fluctuations.
- Each compound had no side effects on the change of the body weights of the mice at the dosage of 1000 mg/Kg.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- The present disclosure claims all the benefits of the patent application No. 201611041317.5 which was filed on Nov. 24, 2016 before the State Intellectual Property Office of the People's Republic of China and was entitled “Use of Piperidine-2,6-dione Derivatives for Treating Ulcerative Colitis”, which is incorporated herein by reference in its entirety.
- The present disclosure relates to organic chemistry and medicinal chemistry fields.
- Crohn's disease is a chronic inflammatory autoimmune disease of the gastrointestinal tract (GI). Crohn's disease can affect any part of the digestive tract from the mouth to the anus. Under the microscope, Crohn's disease affects the entire intestinal wall (transmural injury). Chronic inflammation can cause fibrosis in the subgroup of patients with Crohn's disease, who have the complications including stenosis and fistula, and possibly need repeated surgery. Crohn's disease is associated with increased risk of gastrointestinal malignant tumour. It is found by the study on Crohn's disease that Crohn's disease is associated with TH1 (type 1 T helper cell) and TH17 (type 17 T helper cell) mediated cellular immunity.
- The clinical manifestations of Crohn's disease are various and include gastrointestinal manifestations, systemic manifestations, parenteral manifestations, and complications. Gastrointestinal manifestations mainly include diarrhea, abdominal pain, and bloody stool. Systemic manifestations mainly include weight loss, fever, loss of appetite, fatigue, anemia, and the like. Growth retardation is commonly found in adolescent patients. Common complications include fistula, abdominal abscess, intestinal stenosis, obstruction and perianal lesions. Gastrointestinal bleeding and acute perforation are rare. The long course of disease can lead to cancer. Colonoscopy is generally manifested as segmental and asymmetric various mucosal inflammation, which has the characterized manifestation of non-continuous lesions, longitudinal ulcers and pebble-like appearance. The histopathological changes of Crohn's disease mucosal biopsy samples include: (1) focal discontinuous infiltration of intrinsic membrane inflammatory cells; (2) fissuring ulcers; (3) aphthous ulcers; (4) abnormal crypt structure, glandular hyperplasia, individual crypt abscess, non-obvious reduction of mucus secretion, visible pyloric metaplasia or Paneth cell metaplasia; (5) non-cheese-like necrotic granuloma; (6) chronic inflammatory cell infiltration of lymphocytes and plasma cells, in which the inflammation at the bottom of lamina propria and submucosal layer is severe, and formation of lymph follicle is common; and (7) submucosal lymphatic dilatation; and (8) ganglion cell proliferation and/or ganglion inflammation.
- Mildly active Crohn's disease is treated mainly with 5-aminosalicylic acids and budesonide. If the above treatment is ineffective, Crohn's disease is considered as moderately active. Moderately active Crohn's disease is preferably treated with hormone (such as dexamethasone). If the above treatment is ineffective or becomes dependent, combination with thioglycine or methotrexate will be considered. TNF-α monoclonal antibody can be used if the above hormone therapy and immunotherapy are ineffective or intolerable. Severely active Crohn's disease is treated mainly with systemic hormones, TNF-α monoclonal antibodies and surgery. Drugs for maintenance treatment for Crohn's disease in remission include 5-aminosalicylic acids, thioglycines and TNF-α monoclonal antibodies.
- It is found during the use of 5-aminosalicylic acid drugs (such as sulfasalazine and mesalazine) that about 50% of patients suffer vomiting, anepithymia, liver dysfunction and other digestive disorders, hemolytic anemia and folic acid deficiency anemia and other blood disorders. In addition, since there is a salicylic acid skeleton, there is a possibility that side effects such as diarrhea, abdominal pain, amylase rise, and renal dysfunction occur in cases where the patients have allergic symptoms on salicylic acid agents. Furthermore, because it is discovered that sulfasalazine has side effects of male infertility and colored urine, the patients suffer great mental stress. Due to immunosuppression and short-term efficacy characteristics, budesonide or azathiopurine can also be used, but only in a short term. When the patients are not administered with the biological agents, it will lead to the recurrence of the disease and increase difficulty to treat the disease. Moreover, the biological agents will also give patients a greater financial burden. Monoclonal antibody drugs (such as infliximab and adalimumab) may cause high blood pressure, chills, rash, fever, headache, eczema and so on. As infliximab is a chimeric antibody, it is possible to show antigenicity and sometimes cause acute hypersensitivity.
- Small molecule TNF-α inhibitors such as lenalidomide and thalidomide have been shown to be not effective in the treatment of Crohn's disease (C. Yang et, Aliment Pharmacol Ther 2015; 41:1079-7093.).
- Moreover, Crohn's disease is a chronic disease that requires a longer duration of drugs. The above data show that there is no drug for long-term effective treatment of Crohn's disease, especially drug by oral administration. Therefore, there is a need for developing better target therapy with optimized chronic use for Crohn's disease, or drugs with better effectiveness or better safety.
- Dinitrobenzene sulfonic acid (DNBS) or trinitrobenzene sulfonic acid (TNBS)-induced inflammatory models are widely used to study the mechanism of production of Crohn's disease and the development and assessment of drugs for treating Crohn's disease. See the following reference: Establishment of Inflammatory Bowel Disease Models Induced by 2,4,6-Trinitrobenzenesulfonic, J. Med. Res., July 2008, Vol. 37, No. 7, which are incorporated herein by reference in its entirety.
- Small molecular TNF-α inhibitors such as lenalidomide and thalidomide have been shown to be not effective in the treatment of Crohn's disease (C. Yang et, Aliment Pharmacol Ther 2015; 41:1079-7093.).
- In one aspect, some embodiments disclose a piperidine-2,6-dione derivative of formula (I) and pharmaceutically acceptable salts thereof:
- wherein,
- R1 represents one or more substituents selected from the group consisting of H, halogen, —OH, —C1-4alkyl, —NH2, —NHC1-4alkyl, —N(C1-4alkyl)2 and —NHCOC1-4alkyl;
- R2 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—; and
- R3 represents —H or —C1-4alkyl.
- In another aspect, some embodiments disclose a piperidine-2,6-dione derivative of formula (II) and pharmaceutically acceptable salts thereof:
- wherein,
- R4 represents one or more substituents selected from the group consisting of H, halogen, —C1-4alkyl, —NH2, —NHC1-4alkyl, —N(C1-4alkyl)2 and —NHCOC1-4alkyl;
- R5 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—;
- R6 represents —S—, —SO—, —SO2—, —NH— or —N(C1-4alkyl)-; and
- R7 represents —H or —C1-4alkyl.
- In yet another aspect, some embodiments disclose a piperidine-2,6-dione derivative of formula (III) and pharmaceutically acceptable salts thereof:
- wherein,
- R8 represents one or more substituents selected from the group consisting of H, halogen, —C1-4alkyl, —NH2, —NHC1-4alkyl, —N(C1-4alkyl)2 and —NHCOC1-4alkyl;
- R9 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—;
- R10 represents —O—, —S—, —SO—, —SO2—, —NH— or —N(C1-4alkyl)-;
- R11 represents —H or —C1-4alkyl; and
- R12 represents halogen or —C1-4alkyl.
- All the compounds of formula (I), formula (II) and formula (III) as mentioned above belong to piperidine-2,6-dione derivatives as mentioned herein.
- In still another aspect, some embodiments disclose a piperidine-2,6-dione derivative and pharmaceutically acceptable salts thereof, which are selected from the group consisting of:
- 4-acetylamino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-methylamino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-dimethylamino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-fluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4,5,6,7-tetrafluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-hydroxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 5-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-5-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-5-fluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-7-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methylthioethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methylsulfinylethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methylsulfonylethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methoxyethyl)-3-fluoro-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methoxyethyl)-3-methyl-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-acetylamino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-fluoro-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 5-amino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-fluoro-2-(1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 5-fluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methoxybutyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-methyl-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-5-methoxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof; and
- 4-amino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof.
- In another aspect, some embodiments disclose a pharmaceutical composition comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, and a pharmaceutically acceptable carrier, diluent or excipient.
- In another aspect, some embodiments disclose a method for treating Crohn's disease, comprising administering a therapeutically effective amount of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, or a therapeutically effective amount of the pharmaceutical composition as disclosed herein to a subject in need thereof.
- In another aspect, some embodiments disclose the piperidine-2,6-dione derivative and pharmaceutically acceptable salts thereof of as disclosed herein for treating Crohn's disease.
- In another aspect, some embodiments disclose a pharmaceutical composition for treating Crohn's disease, comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, and a pharmaceutically acceptable carrier, diluent or excipient.
- In the following description, certain specific details are included to provide a thorough understanding for various disclosed embodiments. One skilled in the relevant art, however, will recognize that the embodiments may be practiced without one or more these specific details, or with other methods, components, materials, etc.
- Unless the context required otherwise, throughout the specification and claims which follows, the term “comprise” and variations thereof, such as “comprises” and “comprising” are to be construed in an open, inclusive sense, which is as “include, but not limited to”.
- Reference throughout this specification to “one embodiment”, or “an embodiment”, or “in another embodiment”, or “in some embodiments” means that a particular referent feature, structure or characteristic described in connection with the embodiments is included in at least one embodiment. Therefore, the appearance of the phrases “in one embodiment”, or “in the embodiment”, or “in another embodiment”, or “in some embodiments” in various places throughout this specification are not necessarily all referring to the same embodiment. Moreover, the particular features, structures or characteristics may be combined in any suitable manner in one or more embodiments.
- Accordingly, as used in the specification and appended claims, unless specified to the contrary, the following terms have the meanings indicated: The term “Crohn's disease” is a nonspecific inflammatory disease, of which the etiology is not yet clear. The more specific definition can be found in the following reference: Consensus on diagnosis and treatment of inflammatory bowel disease (2012, Guangzhou), Chinese Journal of Gastroenterology, 2012, 51 (12):763-781, which is incorporated herein by reference in its entirety.
- According to the severity of disease, Crohn's disease can be mild Crohn's disease, moderate Crohn's disease, or severe Crohn's disease. According to the activity of disease, Crohn's disease can be divided into active Crohn's disease or Crohn's disease in remission.
- The goal of treatment for Crohn's disease is to induce active Crohn's disease to enter the remission (i.e, induction of remission) and/or to maintain the disease in remission (i.e., maintenance of remission).
- In clinical studies, the Montreal CD phenotype is a classification method for Crohn's disease. The details are as follows:
-
TABLE 1 Montreal Classification for Crohn’s disease Age at diagnosis (A) A1 16 years or younger A2 between 17 to 40 years A3 over 40 years Location (L) L1 Terminal ileum L1 + L4b L2 Colon L2 + L4b L3 Ileocolon L2 + L4b L4 Upper gastrointestinal Behaviour (B) B1a non-stricturing, non-penetrating B1Pc B2 stricturing B2pc B3 penetrating B3pc Note: aB1 may develop into B2 or B3 when time passes; bL4 may coexist with L1, L2 or L3; cp is perianal disease, which may coexist with B1, B2 or B3 - Clinically, the Crohn's disease activity index (CDAI) can also be used to assess the severity of disease activity and evaluate efficacy. Best CDAI calculation can be referred to. The details are as follows:
-
TABLE 2 Best CDAI Calculation Variable Multiplier Number of liquid stools (in one week) 2 Abdominal pain ratings (in one week, 0-3 points) 5 General well-being (in one week, 0-4 points) 7 Extraintestinal findings and complications (1 point 20 for each item) Opiods antidiarrhoeal drugs (no = 0; yes = 1) 30 Abdominal mass (questionalbel = 2; definite = 5) 10 Haematocrit reduction (Norma: Men: 0.40, 6 Women: 0.37) 100 × (1-observed body weight/ideal body weight) 1 Note: ahaematocrit norm is based on Chinese standard; total point = the sum of the points in each item, where CDAI is < 150, the disease is in remission; where CDAI is ≥ 150 the disease is active; where CDAI is 150-220, disease is mild; where CDAI is 221-450, disease is moderate; where CDAI is > 450, disease is severe. - The patient's disease was scored according to the Best CDAI calculation as described above. After scoring, the clinical remission corresponds to Crohn's disease in remission of the present disclosure, mild activity corresponds to mild Crohn's disease of the present disclosure, moderate activity corresponds to moderate Crohn's disease of the present disclosure, and severe activity corresponds to severe Crohn's disease of the present disclosure.
- Certain chemical groups named herein are preceded by a shorthand notation indicating the total number of carbon atoms that are to be found in the indicated chemical group. For example, C1-C4alkyl describes an alkyl group, as defined below, having a total of 1 to 4 carbon atoms, and C3-C10cycloalkyl describes a cycloaklyl group, as defined below, having a total of 3 to 10 carbon atoms. The total number of carbon atoms in the shorthand notation does not include the carbons that may exist in the substituents of the groups described.
- The term “mammal” means animals including, for example, dogs, cats, cows, sheep, horses, and humans. In some embodiments, mammals include humans.
- The term “patient” means an animal, such as a human, a companion animal, such as a dog, cat and horse, and livestock, such as cattle, swine and sheep. In some embodiments, patients are mammals, including both males and females. In some embodiments, patients are humans.
- The term “pharmaceutically acceptable” as used herein means the carrier, vehicle, diluent, excipient and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.
- “Optional” or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
- “Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isosmotic agent, solvent, or emulsifier, etc, which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or animals and have no side effects on preparing a pharmaceutical composition.
- “Pharmaceutically acceptable salts” include both “pharmaceutically acceptable acid addition salts” and “pharmaceutically acceptable base addition salts”.
- “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but not limited to hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphanic acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleinic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid and the like.
- “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited, to sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminium salts and the like. In some embodiments, inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and s basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucosamine, theobromine, triethanolamine, trometamol, purine, piperazine, piperidine, N-ethyl piperidine, polyamine resins and the like. In some embodiments, organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
- The term “a solvent or a solvent mixture” refers to any and all solvents, In some embodiments, a solvent or a solvent mixture is organic solvents and water, which include, but are not limited to, water, methanol, ethanol, 2-propanol, n-butanol, iso-butanol, acetone, methylethylketone, ethylacetate, 1,4-dioxane, diethylether, MTBE, THF, acetonitrile, dichloromethane, chloroform, DMF, cyclohexane, cyclopentane, n-hexane, n-heptane, n-pentane, toluene, o-xylene, p-xylene, DMSO, pyridine, acetic acid, anisole, butylacetate, cumene, ethylformate, formic acid, iso-butylacetate, iso-propylacetate, methylacetate, 3-methyl-1-butanol, methylisobutylketone, 2-methyl-1-propanol, 1-pentanol, propylacetate, ethylenglycole, and 1-methyl-2-pyrrolidone, as well as any and all mixtures of two or more such solvents. In some embodiments, a solvent or a solvent mixture is single solvent and binary mixtures. In some embodiments, a solvent or a solvent mixture is water and single solvent of organic solvent and binary mixtures of water and organic solvent.
- A “pharmaceutical composition” refers to a formulation of a compound of the present disclosure and a medium generally acceptable in the art for the delivery of the biologically active compound to mammals, e.g., humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.
- “Therapeutically effective amount” refers to an amount of a compound or combination of compounds that ameliorates, attenuates or eliminates a particular disease or condition or a symptom of a particular disease or condition, or prevents or delays the onset of a particular disease or condition or a symptom of a particular disease or condition. The amount of a compound of the present disclosure which constitutes a “therapeutically effective amount” will vary depending on the compound, the condition and its severity, and the age of the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
- “Treating” or “treatment” as used herein covers the treatment of the disease or condition of interest in a mammal, such as a human, having the disease or disorder of interest, and includes:
- (i) preventing the disease or condition from occurring in a mammal, in particular, when such mammal is predisposed to the condition but has not yet been diagnosed as having it;
- (ii) inhibiting the disease or condition, i.e., arresting its development; or
- (iii) relieving the disease or condition, i.e., causing regression of the disease or condition.
- As used herein, the terms “disease” and “condition” may be used interchangeably or may be different in that the particular malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians.
- The compounds of the present disclosure or their pharmaceutically acceptable salt may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereoisomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or (D)- or (L)- for amino acids. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (−), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as HPLC using a chiral column. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
- A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof.
- The substituent position of the compounds disclosed in the present disclosure is numbered as follows:
- The substitution site of R1 in formula (I) can be one of the sites numbered as 4, 5, 6 and 7 or a combination of several sites numbered as 4, 5, 6 and 7. The substitution site of R4 in formula (II) can be one of the sites numbered as 4, 5, 6 and 7 or a combination of several sites numbered as 4, 5, 6 and 7. The substitution site of R8 in formula (III) can be one of the sites numbered as 4, 5, 6 and 7 or a combination of several sites numbered as 4, 5, 6 and 7.
- These and other features, aspects and advantages of the present disclosure will become better understood with reference to the following drawings, description and claims.
- In one aspect, some embodiments disclose a piperidine-2,6-dione derivative of formula I) and pharmaceutically acceptable salts thereof:
- wherein,
- R1 represents one or more substituents selected from the group consisting of H, halogen, —OH, —C1-4alkyl, —NH2, —NHC1-4alkyl, —N(C1-4alkyl)2 and —NHCOC1-4alkyl;
- R2 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—; and
- R3 represents —H or —C1-4alkyl.
- Some embodiments disclose a piperidine-2,6-dione derivative of formula (I) and pharmaceutically acceptable salts thereof:
- wherein,
- R1 represents one or more substituents selected from the group consisting of —H, —F, —Cl, —Br, —OH, —CH3, —CH2CH3, —CH2CH2CH3, —NHCH3, —NH2, —NHCH2CH3, —N(CH3)2, —N(CH2CH3)2, —NHCOCH3 and —NHCOCH2CH3;
- R2 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—; and
- R3 represents —H, —CH3 or —CH2CH3.
- Some embodiments disclose a piperidine-2,6-dione derivative of formula (I) and pharmaceutically acceptable salts thereof:
- wherein,
- R1 represents one or more substituents selected from the group consisting of —H, —F, —OH, —CH3, —NHCH3, —N(CH3)2, —NHCOCH3 and —NH2;
- R2 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—; and
- R3 represents —H, —CH3 or —CH2CH3.
- Some embodiments disclose a piperidine-2,6-dione derivatives of formula (I) and pharmaceutically acceptable salts thereof, which are selected from the group consisting of:
- 4-acetylamino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-methylamino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-dimethylamino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-fluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4,5,6,7-tetrafluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-hydroxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 5-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-5-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-5-fluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-7-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-acetylamino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-fluoro-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 5-amino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-fluoro-2-(1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 5-fluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methoxybutyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-methyl-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-5-methoxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof; and
- 4-amino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof.
- In one aspect, some embodiments disclose a piperidine-2,6-dione derivative of formula (II) and pharmaceutically acceptable salts thereof:
- wherein,
- R4 represents one or more substituents selected from the group consisting of H, halogen, —C1-4alkyl, —NH2, —NHC1-4alkyl, —N(C1-4alkyl)2 and —NHCOC1-4alkyl;
- R5 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—;
- R6 represents —S—, —SO—, —SO2—, —NH— or —N(C1-4alkyl)-; and
- R7 represents —H or —C1-4alkyl.
- Some embodiments disclose a piperidine-2,6-dione derivative of formula (II) and pharmaceutically acceptable salts thereof:
- wherein,
- R4 represents one or more substituents selected from the group consisting of —H, —F, —Cl, —Br, —OH, —CH3, —NHCH3, —NHCH2CH3, —NH2, —N(CH3)2, —N(CH2CH3)2, —NHCOCH3 and —NHCOCH2CH3;
- R5 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—;
- R6 represents —S—, —SO—, —SO2—, —NH— or —N(CH3)—; and
- R7 represents —H, —CH3 or —CH2CH3.
- Some embodiments disclose a piperidine-2,6-dione derivative of formula (II) and pharmaceutically acceptable salts thereof:
- wherein,
- R4 represents —NH2 or —NHCOCH3;
- R5 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—;
- R6 represents —S—, —SO—, —SO2—, —NH— or —N(CH3)—; and
- R7 represents —H, —CH3 or —CH2CH3.
- Some embodiments disclose a piperidine-2,6-dione derivative of formula (II) and pharmaceutically acceptable salts thereof:
- 4-amino-2-(1-(2-methylthioethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methylsulfinylethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof; and
- 4-amino-2-(1-(2-methylsulfonylethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof.
- In yet another aspect, some embodiments disclose a piperidine-2,6-dione derivative of formula (III) and pharmaceutically acceptable salts thereof:
- wherein,
- R8 represents one or more substituents selected from the group consisting of H, halogen, —C1-4alkyl, —NH2, —NHC1-4alkyl, —N(C1-4alkyl)2 and —NHCOC1-4alkyl;
- R9 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—;
- R10 represents —O—, —S—, —SO—, —SO2—, —NH— or —N(C1-4alkyl)-;
- R11 represents —H or —C1-4alkyl; and
- R12 represents halogen or —C1-4alkyl.
- Some embodiments disclose a piperidine-2,6-dione derivative of formula (III) and pharmaceutically acceptable salts thereof:
- wherein,
- R8 represents one or more substituents selected from the group consisting of —H, —F, —Cl, —Br, —OH, —CH3, —NHCH3, —NHCH2CH3, —NH2, —N(CH3)2, —N(CH2CH3)2, —NHCOCH3 and —NHCOCH2CH3;
- R9 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—;
- R10 represents —O—, —S—, —SO—, —SO2—, —NH— or —N(CH3)—;
- R11 represents —H, —CH3 or —CH2CH3; and
- R12 represents halogen or —C1-4alkyl.
- Some embodiments disclose a piperidine-2,6-dione derivative of formula (III) and pharmaceutically acceptable salts thereof:
- wherein,
- R8 represents —NH2 or —NHCOCH3;
- R9 represents —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—; R10 represents —O—, —S—, —SO—, —SO2—, —NH— or —N(CH3)—;
- R11 represents —H, —CH3 or —CH2CH3; and
- R12 represents halogen or —C1-4alkyl.
- Some embodiments disclose a piperidine-2,6-dione derivative of formula (III) and pharmaceutically acceptable salts thereof, which are selected from the group consisting of:
- 4-amino-2-(1-(2-methoxyethyl)-3-fluoro-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof; and
- 4-amino-2-(1-(2-methoxyethyl)-3-methyl-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof.
- All the compounds of formula (I), formula (II) and formula (III) as mentioned above belong to piperidine-2,6-dione derivatives as mentioned herein.
- Some embodiments disclose a piperidine-2,6-dione derivatives and pharmaceutically acceptable salts thereof, which are selected from the group consisting of:
- 4-acetylamino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-methylamino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-dimethylamino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-fluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4,5,6,7-tetrafluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-hydroxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 5-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-5-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-5-fluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-7-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methylthioethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methylsulfinylethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methylsulfonylethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methoxyethyl)-3-fluoro-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methoxyethyl)-3-methyl-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-acetylamino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-fluoro-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 5-amino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-fluoro-2-(1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 5-fluoro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methoxybutyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-methyl-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-5-methoxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione and pharmaceutically acceptable salts thereof;
- 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof; and
- 4-amino-2-(1-(2-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione and pharmaceutically acceptable salts thereof.
- In still another aspect, some embodiments disclose a pharmaceutical composition comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, and a pharmaceutically acceptable carrier, diluent or excipient.
- In yet another aspect, some embodiments disclose a method for treating Crohn's disease, comprising administering a therapeutically effective amount of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, or a therapeutically effective amount of the pharmaceutical composition as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, comprising administering 1 mg-10 g of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, comprising administering 10 mg-3000 mg of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, comprising administering 100 mg-1000 mg of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, comprising administering 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg or 1000 mg of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, wherein the Crohn's disease is mild Crohn's disease, moderate Crohn's disease, severe Crohn's disease or Crohn's disease in remission.
- Some embodiments disclose a method for treating Crohn's disease, wherein the subject in need thereof is a mammal.
- Some embodiments disclose a method for treating Crohn's disease, wherein the subject in need thereof is human.
- Some embodiments disclose of a method of maintenance treatment of Crohn's disease, comprising administering a therapeutically effective amount of the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, or a therapeutically effective amount of the pharmaceutical composition as disclosed herein to a subject in need thereof.
- Some embodiments disclose a method for treating Crohn's disease, wherein the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, or the pharmaceutical composition comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein is administered orally.
- Some embodiments disclose a method for treating Crohn's disease, wherein the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, or the pharmaceutical composition comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein is administered orally in a solid or liquid formulation.
- Exemplary examples of the solid formulation that can be used in the method for treating Crohn's disease as disclosed herein comprise, but are not limited to, a tablet, capsule and sugar-coated pill.
- Exemplary examples of the tablet that can be used in the method for treating Crohn's disease as disclosed herein comprise, but are not limited to, a plain tablet, sugar-coated tablet and film-coated tablet.
- Exemplary examples of the liquid formulation that can be used in the method for treating Crohn's disease as disclosed herein comprise, but are not limited to, a solution and suspension.
- In yet another aspect, some embodiments disclose a piperidine-2,6-dione derivative and pharmaceutically acceptable salts thereof for treating Crohn's disease.
- In still another aspect, some embodiments disclose a pharmaceutical composition for treating Crohn's disease, comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, and a pharmaceutically acceptable carrier, diluent or excipient.
- The piperidine-2,6-dione derivatives as disclosed herein have good therapeutical effects.
- The piperidine-2,6-dione derivatives as disclosed herein have better safety.
- The piperidine-2,6-dione derivatives as disclosed herein have better tolerance.
- Some embodiments disclose a pharmaceutical composition comprising the piperidine-2,6-dione derivative or pharmaceutically acceptable salts thereof as disclosed herein, and a pharmaceutically acceptable carrier, diluent or excipient.
- In some embodiments, the route of administration of the piperidine-2,6-dione derivatives as disclosed herein to the mammals can be non-parenteral route.
- In some embodiments, the route of administration of the piperidine-2,6-dione derivatives as disclosed herein to the mammals can be oral route.
- In some embodiments, the route of administration of the piperidine-2,6-dione derivatives as disclosed herein to the mammals can be intrarectal route.
- The piperidine-2,6-dione derivatives as described herein may be obtained in any suitable form such as tablet, capsule, powder, oral solution, suspension, rectal gel, rectal foam, rectal enema or suppository and the like. Exemplary examples of tablets comprise, but are not limited to, plain tablets, sugar-coated tablets and film-coated tablets.
- Examples of a pharmaceutically acceptable carrier that can be used in the pharmaceutical composition of the present disclosure include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isosmotic agent, solvent or emulsifier, which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or animals. Acceptable carriers or diluents for therapeutic use are well-known in the art, and are described, for example, in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, Pa. (1990), which is incorporated herein by reference in its entirety.
- The pharmaceutical compositions of the present disclosure may be administered by any means that achieve their intended purpose. For example, administration may be by oral, parenteral, topical, enteral, intravenous, intramuscular, inhalant, nasal, intraarticular, intraspinal, transtracheal, transocular, subcutaneous, intraperitoneal, transdermal, or buccal routes. The route of administration can be non-parenteral route, oral route and intrarectal route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- Suitable dosage forms include, but are not limited to capsules, tablets, pellets, dragees, semi-solids, powders, granules, suppositories, ointments, creams, lotions, inhalants, injections, cataplasms, gels, tapes, eye drops, solution, syrups, aerosols, suspension, emulsion, which can be produced according to methods known in the art.
- Particularly suitable for oral use are ordinary tablets (plain tablets), sugar-coated tablet, film-coated tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops, suitable for rectal use are suppositories, suitable for parenteral use are solutions, or oil-based or aqueous solutions, furthermore suspensions, emulsions or implants, and suitable for topical use are ointments, creams or powders. The compounds of the present disclosure may also be lyophilised and the resultant lyophilisates used, for example, for the preparation of injection preparations. The preparations indicated may be sterilised and/or comprise assistants, such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, dyes, flavours and/or a plurality of further active ingredients, for example one or more vitamins.
- In some embodiments, a pharmaceutical composition of the present disclosure is formulated as tablet, solution, granule, patch, ointment, capsule, aerosol or suppository administered via parenteral, transdermal, mucosa, nasal, buccal, sublingual or oral route.
- Preservatives, stabilizers, dyes, sweeteners, flavoring agents, fragrances, and the like, may be provided in the pharmaceutical composition. For example, sodium benzoate, ascorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives. Furthermore, antioxidants and suspending agents may be used.
- In various embodiments, alcohols, esters, sulfating aliphatic alcohols, and the like may be used as surfactants; sucrose, glucose, lactose, starch, crystalline cellulose, mannitol, light anhydrous silicate, magnesium aluminate, methyl magnesium silicate aluminate, synthetic aluminum silicate, calcium carbonate, calcium bicarbonate, calcium hydrogenphosphate, calcium hydroxymethyl cellulose and the like may be used as excipients; magnesium stearate, tale, hardened oil may be used as smoothing agents; coconut oil, olive oil, sesame oil, peanut oil, soybean may be used as suspending agents or lubricants; cellulose acetate phthalate as a derivative of a carbohydrate such as cellulose or sugar, or methylacetate-methacrylate copolymer as a derivative of polyethylene may be used as suspending agents; and plasticizers such as ester phthalates and the like may be used as suspending agents.
- Suitable routes of administration may, for example, include oral, rectal, transmucosal, topical, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal or intraocular injections. The compound can be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills, transdermal (including electromigrating) patches, and the like for prolonged and/or timed, pulsed administration at a predetermined rate.
- Pharmaceutical compositions of the present disclosure may be manufacture in manner that is itself known, for example, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or tabletting processes.
- Pharmaceutical compositions for use in accordance with the present disclosure thus may be formulated by a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing the active compounds into preparation which can be used pharmaceutically. Proper formulation is dependent on the route of administration chosen. Any of the well-known techniques, carriers and excipients may be used as suitable and as understood in the art.
- Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, glucose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, and the like. Furthermore, if desired, the injectable pharmaceutical compositions may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like. Physiologically compatible buffers include, but are not limited to, Hank's solution, Ringer's solution or physiological saline buffer. If desired, absorption enhancing preparations (such as liposomes) may be used.
- For oral administration, the compound can be formulated readily by combining the active compound with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compound of the disclosure to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, ointments, suspensions, and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparation for oral use can be obtained by combining the active compound with solid excipient, optionally grinding a resultant mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, saccharose, mannitol or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the crosslinked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solution, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added into the tablets or dagree coatings for identification or to characterizing different combinations of active compound doses. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, tale, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solution, and suitable organic solvents or solvent mixtures.
- Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain active ingredients in admixture with filler such as sugar, binders such as starches, and/or lubricants such as tale or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oil, liquid paraffin, or liquid polyethylene glycols. Furthermore, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
- In some embodiments, the pharmaceutical composition of the present disclosure may comprise 0.1%-95% of the piperidine-2,6-dione derivatives as disclosed herein.
- In some embodiments, the pharmaceutical composition of the present disclosure may comprise 1%-70% of the piperidine-2,6-dione derivatives as disclosed herein.
- Under any circumstances, the composition or formulation to be administered may comprise some amount of the piperidine-2,6-dione derivatives as disclosed herein, which is effective to treat the disease/condition of a study subject to be treated.
- At least one of the compounds of the present disclosure or the pharmaceutical compositions comprising at least one of the compounds of the present disclosure may be administered to the patient by any suitable means and/or by any means that topically delivers the compounds of the present disclosure. Non-limiting examples of methods of administration include, among others, (a) administration though oral pathways, which administration includes administration in capsule, tablet, granule, spray, syrup, or other such forms; (b) administration through non-oral pathways such as rectal, vaginal, intraurethral, intraocular, intranasal, or intrarticular, which administration includes administration as an aqueous suspension, an oily preparation or the like or as a drip, spray, suppository, salve, ointment or the like; (c) administration via injection, subcutaneously, intraperitoneally, intravenously, intramuscularly, intradermally, intraorbitally, intracapsularly, intraspinally, intrasternally, or the like, including infusion pump delivery; (d) administration locally such as by injection directly in the renal or cardiac area, e.g., by depot implantation; as well as (e) administration topically; as deemed appropriate by those of skill in the art for bringing the compound of the present disclosure into contact with living tissue.
- The most suitable route depends on the nature and severity of the condition to be treated. A person having ordinary skill in the art also knows determination of methods of administration (buccal, intravenous, inhalation subcutaneous, rectal and the like), dosage form, suitable pharmaceutical excipients and other events regarding delivering the compound to a subject in need thereof.
- Pharmaceutical compositions suitable for administration include compositions where the active ingredients are contained in an amount effective to achieve its intended purpose. The therapeutically effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including human, being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- As will be readily apparent to one skilled in the art, the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed. The determination of effective dosage levels, that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.
- In non-human animal studies, applications of potential products are commenced at higher dosage levels, with dosage being decreased until the desired effect is no longer achieved or adverse side effects disappear. The dosage may range broadly, depending upon the desired affects and the therapeutic indication. Typically, dosages may be between about 10 microgram/kg and 1000 mg/kg body weight, in some embodiments, between about 100 microgram/kg and 300 mg/kg body weight. Alternatively dosages may be based and calculated upon the surface area of the patient, as understood by those of skill in the art.
- The exact formulation, route of administration and dosage for the pharmaceutical compositions of the present disclosure can be chosen by the individual physician in view of the patient's condition. Typically, the dose range of the composition administered to the patient can be from about 0.5 to 1000 mg/kg of the patient's body weight. The dosage may be a single one or a series of two or more given in the course of one or more days, as is needed by the patient. In instances where human dosages for compounds have been established for at least some condition, the present disclosure will use those same dosages, or dosages that are between about 0.1% and 500%, in some embodiments, between about 25% and 250% of the established human dosage. Where no human dosage is established, as will be the case for newly-discovered pharmaceutical compounds, a suitable human dosage can be inferred from ED50 or ID50 values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.
- It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity or organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
- Although the exact dosage will be determined on a drug-by-drug basis, in most cases, some generalizations regarding the dosage can be made. The daily dosage regimen for an adult human patient may be, for example, an oral dose of between 0.1 mg and 2000 mg of each active ingredient, in some embodiments, between 1 mg and 2000 mg, e.g. 5 to 1500 mg. In other embodiments, an intravenous, subcutaneous, or intramuscular dose of each active ingredient of between 0.01 mg and 1000 mg, in some embodiments, between 0.1 mg and 1000 mg, e.g. 1 to 800 mg is used. In cases of administration of a pharmaceutically acceptable salt, dosages may be calculated as the free base. In some embodiments, the composition is administered 1 to 4 times per day. Alternatively the compositions of the disclosure may be administered by continuous intravenous infusion, in some embodiments, at a dose of each active ingredient up to 2000 mg per day. As will be understood by those of skill in the art, in certain situations it may be necessary to administer the compounds disclosed herein in amounts that exceed, or even far exceed, the above-stated dosage range in order to effectively and aggressively treat particularly aggressive diseases or infections. In some embodiments, the compounds will be administered for a period of continuous therapy, for example for a week or more, or for months or years.
- Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.
- Dosage intervals can also be determined using MEC value. Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, in some embodiments, between 30-90% and in some embodiments, between 50-90%.
- In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.
- The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
- Compounds disclosed herein can be evaluated for efficacy and toxicity using known methods. For example, the toxicology of a particular compound, or of a subset of the compounds, sharing certain chemical moieties, may be established by determining in vitro toxicity towards a cell line, such as a mammalian, and in some embodiments, human, cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans. Alternatively, the toxicity of particular compounds in an animal model, such as mice, rats, rabbits, or monkeys, may be determined using known methods. The efficacy of a particular compound may be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials. Recognized in vitro models exist for nearly every class of condition, including but not limited to cancer, cardiovascular disease, and various immune dysfunction. Similarly, acceptable animal models may be used to establish efficacy of chemicals to treat such conditions. When selecting a model to determine efficacy, the skilled artisan can be guided by the state of the art to choose an appropriate model, dose, and route of administration, and regime. Of course, human clinical trials can also be used to determine the efficacy of a compound in humans.
- The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Compositions comprising a compound of the disclosure formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- The following abbreviations were used in the discussion, examples and preparations.
- LPS: lipopolysaccharide;
- PBS: phosphate buffered saline;
- Tween-20
- PBST: 0.05% of Tween-20 in phosphate buffered saline;
- HRP: horseradish peroxidase;
- TMB: 3,3′,5,5′-tetramethylbenzidine;
- DSS: dextra sulfate sodium;
- 5-ASA: 5-aminosalicylic acid;
- CMC-Na: sodium carboxymethyl cellulose;
- DNBS: dinitrobenzenesulfonic acid;
- 1% CMC-Na: 1% (weight/volume) of CMC-Na in water;
- 1.6% DSS: 1.6% (weight/volume) of DSS in water;
- 0.9% DSS: 0.9% (weight/volume) of DSS in water;
- mg/Kg: milligram/kilogram;
- mg/Kg/d: milligram/kilogram/day;
- ml/Kg: milliliter/kilogram;
- cm: centimeter;
- Mean±SD: Mean±standard deviation;
- 30% ethanol: 30% (volume/volume) of ethanol in water;
- cm2: square centimeter;
- U/mg: unit/milligram;
- g: gram;
- mmol: millimole;
- mol/L: mole/liter;
- i.g: intragastric administration;
- ml: milliliter;
- MPO: myeloperoxidase;
- μL: microliter;
- nm: nanometer;
- s: second;
- OD value: optical density value;
- μm: micron;
- Qd, QD, Q.D or qd: once a day;
- The following instruments or devices may be used in the experiments:
-
Instruments Type Company Animal Endoscopy VET-6011 Shanghai Aohua Endoscopy Co., Ltd. FullyAutomated Cobas c 311 Roche Biochemical Analyzer ELIASA Multiskan GO Thermo Scientific ELIASA Model 680 Biorad Microplate Washer Model 1575 Biorad Animal Fixator Chinese Patent No. Suzhou Monkey Animal ZL 200800089997.7 ExperimentalEquipment Technology Co., Ltd. High-speed Centrifuge TGL-16B Shanghai Anting Scientific Instrument Factory Triple Quadrupole APB 000 Applied Biosystems Mass Spectrometer (TQMS) High Performance LC-20A Shimadzu Corporation Liquid Chromatography (HPLC) Vortex Mixer QL901 Haimen Kylin-Bell Lab Instruments Co., Ltd. Low-temperature HeraeusMultifuge Thermo Scientific High-speed Centrifuge X3R Fully Automated Leica ASP200S Leica Instruments Vacuum Processor Germany GmbH Embedding Machine Leica EG1150H+C Leica Instruments Germany GmbH Manual Microtome Leica RM2235 Leica Instruments Germany GmbH Water Bath for Paraffin Leica-HI1210 Leica Instruments Sections Germany GmbH Fully Automated Leica-ST5020 Leica Instruments Stainer Germany GmbH Fully Automated Glass Leica CV5030 Leica Instruments Coverslipper Germany GmbH - The Chinese patent No. ZL200510013292.3 discloses the preparation process of 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione, which is incorporated herein by reference in its entirety.
- 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione was prepared in accordance with the process disclosed in the Chinese patent No. ZL200510013292.3.
- In dichloromethane (DCM) (30 mL) was dissolved 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione (3.0 g). Triethylamine (TEA) (2.75 g, 3.77 mL) and 4-dimethylaminopyridine (DMAP) (0.126 g) were added into the solution. The air was replaced with argon. The temperature of the reaction system was lowered to 0° C. To the reaction system was added acetyl chloride (4.59 g, 4.16 mL) with stirring. The temperature of the reaction system was slowly heated to the room temperature until the reaction was complete. To the reaction solution was added water (60 mL) to quench the reaction. The solution was extracted once with dichloromethane. The organic phase was washed once with saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and filtered. The solvent was evaporated under reduced pressure to give a crude product. The crude product was purified with silica gel column chromatography to give a solid product (1.8 g). The solid product was dissolved with dichloromethane. To the solution was added dropwise diethyl ether to separate out a product. The resultant product was dissolved with dichloromethane. To the solution was added diethyl ether to separate out a product. The resultant product was dried under reduced pressure to give the title compound of Example 1 as a white solid (1.3 g) (HPLC purity: 98.06%). Yield: 38.3%.
- 1HNMR (deuterated chloroform (CDCl3), 400 MHz) δ 9.411 (bs, 1H), 8.823-8.802 (d, 1H), 7.730-7.690 (dd, 1H), 7.557-7.537 (dd, 1H), 4.995-4.950 (m, 1H), 4.146-4.001 (m, 2H), 3.555-3.521 (m, 2H), 3.345 (s, 3H), 3.048-2.956 (m, 1H), 2.848-2.719 (m, 2H), 2.267 (s, 3H), 2.186-2.086 (m, 1H). MS(m/e): 374.21 (M+H+).
- To a reaction flask were added 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione (4.0 g), di-tert-butyl dicarbonate (10.528 g) and 4-dimethylaminopyridine (0.147 g). To the reaction flask was added tetrahydrofuran (40 mL). The solution was stirred at the room temperature overnight. The reaction solution was concentrated under reduced pressure to give a crude product. The crude product was purified with silica gel column chromatography to give 4-di-BOC-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione (3.3 g) as a white solid. Yield: 74.1%. MS(m/e): 554.40 (M+Na+).
- 4-di-BOC-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione (2.05 g) was dissolved in dichloromethane (600 mL). To the solution was added tetrahydrofuran (3 mL). The reaction solution was stirred at the room temperature until the reaction was complete. To the resultant solution was added saturated aqueous solution of sodium carbonate to quench the reaction. The solution was separated. The organic phase was dried over anhydrous magnesium sulfate and filtered to give a filtrate. The filtrate was concentrated under reduced pressure to give 4-BOC-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione (1.66 g) (HPLC purity: 98.62%). Yield: 100%. MS(m/e): 454.29 (M+Na+).
- To a reaction flask were added 4-Boc-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione (3.0 g), methyl iodide (2.96 g) and potassium carbonate (2.88 g). To the reaction flask was added N,N-dimethylformamide (30 mL). The reaction solution was stirred at the room temperature overnight. The reaction solution was diluted with dichloromethane (100 mL). The organic phase was washed with water. The aqueous phase was extracted with dichloromethane. The organic phases were combined. The combined organic phase was washed with saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and filtered to give a filtrate. The filtrate was concentrated under reduced pressure to give a crude product. The crude product was purified with silica gel column chromatography to give 4-BOC-methylamino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione as a yellow oil (2.91 g) (HPLC purity: 96.43%). Yield: 94.0%. MS(m/e): 468.31 (M+Na+).
- 4-BOC-methylamino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-iso indolin-1,3-dione (2.9 g) was dissolved in dichloromethane (30 mL). To the solution was added tetrahydrofuran (6 mL). The reaction solution was stirred at the room temperature over 2 hours. The resultant solution was concentrated under reduced pressure to give a crude product. The crude product was dissolved in methyl tert-butyl ether (35 mL). The solution was stirred overnight to separate out a yellow solid product and filtered. The product was dried under reduced pressure to give the title compound as a yellow solid (1.83 g) (HPLC purity: 98.62%). Yield: 81.6%.
- 1HNMR(CDCl3, 400 MHz) δ 7.538-7.499 (dd, 1H), 7.112-7.094 (d, 1H), 6.887-6.866 (d, 1H), 4.949-4.904 (m, 1H), 4.122-3.999 (m, 2H), 3.543-3.510 (m, 2H), 3.341 (s, 3H), 2.989-2.950 (m, 1H), 2.981 (s, 3H), 2.820-2.700 (m, 2H), 2.115-2.060 (m, 1H). MS(m/e): 346.24 (M+H+).
- To a pressure-resistant reaction tube were added 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione (3.0 g), methyl iodide (14.2 g) and potassium carbonate (6.25 g). To the pressure-resistant reaction tube was added N,N-dimethylformamide (20 mL). The reaction tube was sealed and heated to 80° C. in an oil bath. The reaction solution was stirred over 80 hours. The resultant solution was diluted with dichloromethane (200 mL) and filtered to give a filtrate. The filtrate was concentrated under reduced pressure to give a black oily crude product. The crude product was purified with silica gel column chromatography to give a brown solid (3.2 g). The brown solid was dissolved in ethyl acetate (20 mL) and stirred overnight. The resultant solution was filtered to give a solid. The solid was dried under reduced pressure to give the title compound as a yellow powdery solid (1.67 g) (HPLC purity: 97.22%). Yield: 51.4%.
- 1HNMR(CDCl3, 400 MHz) δ 7.543-7.504 (dd, 1H), 7.308-7.287 (d, 1H), 7.121-7.100 (d, 1H), 5.004-4.959 (m, 1H), 4.115-3.999 (m, 2H), 3.537-3.507 (m, 2H), 3.337 (s, 3H), 3.108 (s, 6H), 2.982-2.944 (m, 1H), 2.803-2.751 (m, 2H), 2.094-2.079 (m, 1H). MS(m/e): 360.27 (M+H+).
- To a reaction flask were added 1-(2-methoxyethyl)-3-benzyloxyamido-2,6-piperidinedione acetate (35 g), palladium on carbon (3.5 g, content of palladium: 10%) and acetic acid (13 mL). The air in the flask was replaced with hydrogen three times. The reaction solution was stirred at the room temperature over 72 hours. The resultant solution was filtered to give a filtrate, which was directly used in the next step.
- To a reaction flask were added the above filtrate (comprising 2.0 g (calculated) of 1-(2-methoxyethyl)-3-amino-2,6-piperidinedione acetate), 3-fluorophthalic anhydride (1.35 g), sodium acetate (0.67 g) and acetic acid (43 mL). The solution was heated to 140° C. in an oil bath and stirred to react over 5 hours. The resultant solution was concentrated under reduced pressure to give a black crude product. The crude product was purified with silica gel column chromatography to give the title compound as a white solid (1.56 g) (HPLC purity: 99.88%). Yield: 57.4%.
- 1HNMR (CDCl3, 400 MHz) δ 7.796-7.746 (m, 1H), 7.717-7.700 (d, 1H), 7.447-7.403 (m, 1H), 5.028-4.982 (m, 1H), 4.127-3.998 (m, 2H), 3.541-3.510 (m, 2H), 3.340 (s, 3H), 3.019-2.951 (m, 1H), 2.895-2.739 (m, 2H), 2.171-2.085 (m, 1H). MS(m/e): 357.19 (M+Na+).
- Using the preparation process in Example 4, 2,3,4,5-tetrafluorophthalic anhydride and 1-(2-methoxyethyl)-3-amino-2,6-piperidinedione acetate were reacted to give the title compound as a white solid (2.93 g) (HPLC purity: 97.58%). Yield: 78.6%.
- 1HNMR (CDCl3, 400 MHz) δ 4.999-4.953 (m, 1H), 4.118-3.984 (m, 2H), 3.530-3.500 (m, 2H), 3.333 (s, 3H), 3.029-2.991 (m, 1H), 2.803-2.764 (m, 2H), 2.136-2.117 (m, 1H). MS(m/e): 389.22 (M+H+).
- To a reaction flask were added 3-amino-N-(2,6-dioxo-3-piperidinyl) phthalimide (3.5 g), 2-bromoethanol (4.8 g), potassium carbonate (1.77 g) and N,N-dimethylformamide (35 mL). The reaction flask was heated to 40° C. in an oil bath. The reaction solution was stirred over 80 hours. The reaction system was cooled to the room temperature. To the reaction system was added water (80 mL) to quench the reaction. To the solution was added ethyl acetate. The resultant solution was stirred to separate out a solid. The resultant mixture was filtered under reduced pressure. The filter cake was discarded and the filtrate was collected and separated. The aqueous phase was back-extracted with ethyl acetate four times. The organic phases were combined. The combined organic phase was washed with saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and filtered. The organic phase was concentrated under reduced pressure to give a crude product. The crude product was purified with silica gel column chromatography to give the title compound as a yellow solid (2.0 g) (HPLC purity: 95.53%). Yield: 49.2%.
- 1HNMR (CDCl3, 400 MHzz) δ 7.457-7.419 (t, 1H), 7.176-7.158 (d, 1H), 6.886-6.865 (d, 1H), 4.990-4.945 (m, 1H), 4.135-4.065 (m, 2H), 3.813-3.785 (m, 2H), 3.006-2.966 (m, 1H), 2.829-2.714 (m, 2H), 2.153-2.114 (m, 1H). MS(m/e): 340.18 (M+Na+).
- Using the preparation process in Example 4, 4-nitrophthalic anhydride and 1-(2-methoxyethyl)-3-amino-2,6-piperidinedione acetate were reacted to give 5-nitro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione as a white solid (2.8 g) (HPLC purity: 99.62%). Yield: 54.5. MS(m/e): 384.18 (M+Na+).
- To a reaction flask were added 5-nitro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione (2.6 g), palladium on carbon (0.26 g) and tetrahydrofuran (30 mL). The air in the flask was replaced with hydrogen three times. The reaction solution was stirred at the room temperature over 20 hours until the reaction was complete. The resultant solution was filtered to give a filtrate. The filtrate was concentrated under reduced pressure with water pump to give a crude product. The crude product was dissolved and purified with ethyl acetate to give the title compound as a yellow solid (1.56 g) (HPLC purity: 95.74%). Yield: 65.4%.
- 1HNMR (CDCl3, 400 MHz) δ 7.607-7.587 (d, 1H), 7.012-7.007 (d, 1H), 6.846-6.820 (dd, 1H), 4.970-4.925 (m, 1H), 4.135-3.982 (m, 2H), 3.540-3.509 (m, 2H), 3.340 (s, 3H), 3.024-2.903 (m, 1H), 2.829-2.710 (m, 2H), 2.117-2.062 (m, 1H). MS(m/e): 354.22 (M+Na+).
- To a reaction flask were added 4-hydroxyphthalate dimethyl (125 g) and concentrated sulfuric acid (600 mL). The solution was stirred and cooled to 0° C. To the reaction system was slowly added dropwise fuming nitric acid (39.44 g). The temperature of the reaction system was controlled to be below 5° C. The addition of fuming nitric acid was complete in about 1 hour. The ice bath was removed. The solution was heated to the room temperature and stirred over 22 hours until the reaction was complete. The resultant solution was slowly poured into ice water to quench the reaction. The aqueous phase was extracted with ethyl acetate five times. The organic phases were combined. The combined organic phase was dried over anhydrous magnesium sulfate and filtered. The filtrate was collected and concentrated under reduced pressure with water pump and oil pump successively to give 4-hydroxy-3-nitrophthalate dimethyl (169 g) (HPLC purity: 36.54%), which was directly used in the next step. MS(m/e): 254.07 (M−H)−.
- To a reaction flask were added 4-hydroxy-3-nitrophthalate dimethyl (164 g), benzyl bromide (135.9 g), potassium carbonate (400 g) and acetone (1730 mL). The reaction flask was heated to 70° C. in an oil bath. The solution was stirred over 23 hours until the reaction was complete. The reaction system was cooled to the room temperature and concentrated under reduced pressure. The filter cake was washed with dichloromethane. The filtrate was collected and concentrated under reduced pressure. To the concentrate were added dichloromethane (2000 mL) and saturated aqueous solution of sodium chloride (1000 mL). The resultant solution was extracted.
- The organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to give a yellow solid crude product. The crude product was recrystallized and purified with ethyl acetate to give 4-benzyloxy-3-nitrophthalate dimethyl as a white solid (40 g) (HPLC purity: 96.96%). Yield: 18.1%. MS(m/e): 346.14 (M+H+).
- To a reaction flask were added 4-benzyloxy-3-nitrophthalate dimethyl (30 g) and ethanol (300 mL). To the reaction flask was added preformulated aqueous solution of sodium hydroxide (24 g of sodium hydroxide in 300 mL of water). The reaction flask was heated to 70° C. in an oil bath. The solution was stirred over 7 hours until the reaction was complete. The reaction system was cooled to the room temperature and concentrated under reduced pressure to evaporate most of ethanol. To the concentrate was added 4 N hydrochloric acid at the room temperature until the pH of the solution was adjusted to 2 such that a lot of white solids were separated out. The resultant mixture was filtered under reduced pressure. The filter cake was collected and dried under reduced pressure with oil pump to give 4-benzyloxy-3-nitrophthalic acid as a white solid (27.5 g) (HPLC purity: 99.55%). Yield: 100%. MS(m/e): 316.15 (M−H)−.
- To a reaction flask were added 4-benzyloxy-3-nitrophthalic acid (19.1 g) and acetic anhydride (120 mL). The flask was heated to 140° C. in an oil bath. The solution was stirred over 6 hours. The reaction system was cooled to the room temperature. The resultant solution was concentrated under reduced pressure to give a crude product. The crude product was dissolved and purified with methyl tert-butyl ether and n-hexane to give 4-benzyloxy-3-nitrophthalic anhydride as a brown solid (16.8 g). Yield: 93.3%.
- Using the preparation process in Example 4, 4-benzyloxy-3-nitrophthalic anhydride and 1-(2-methoxyethyl)-3-amino-2,6-piperidinedione acetate were reacted to prepare 4-nitro-5-benzyloxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione as a white solid (22.3 g) (HPLC purity: 99.69%). Yield: 85.0%. MS(m/e): 468.22 (M+H+).
- Using the preparation process in Example 7, 4-nitro-5-benzyloxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione was used to give the title compound as a yellow solid (18.4 g) (HPLC purity: 99.03%). Yield: 86.8%.
- 1HNMR (dimethyl sulfoxide (DMSO), 400 MHz) δ 10.820 (s, 1H), 6.974-6.955 (d, 1H), 6.915-6.896 (d, 1H), 5.936-5.935 (bs, 2H), 5.099-5.053 (q, 1H), 3.917-3.730 (m, 2H), 3.363-3.331 (t, 2H), 3.217 (s, 3H), 3.002-2.911 (m, 1H), 2.762-2.702 (m, 1H), 2.560-2.450 (m, 1H), 2.027-1.963 (m, 1H). MS(m/e): 348.17 (M+H+).
- To a reaction flask were added 4-fluorophthalic acid (1.0 g) and concentrated sulfuric acid (5 mL). The solution was stirred and cooled to 0° C. To the reaction system was slowly added dropwise concentrated nitric acid (1.05 g, content: 65%). After the addition was complete, the resultant solution was heated to 80° C. in an oil bath. The solution was stirred over 7 hours. HPLC was used to monitor the reaction until the reaction was complete. The resultant solution was slowly poured into ice water (20 g) to quench the reaction. The aqueous phase was extracted with ethyl acetate. The organic phases were combined. The combined organic phase was washed with saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and filtered. The filtrate was collected and concentrated under reduced pressure with water pump and oil pump successively to give a yellow solid (1.3 g), which was directly used in the next step.
- To a reaction flask was added thionyl chloride (5 mL). The reaction system was heated to 90° C. in an oil bath and stirred over 11 hours. The reaction system was then cooled to the room temperature. The reaction solution was concentrated under reduced pressure with water pump to give a crude product as a yellow oil (0.56 g), which was directly used in the next step.
- Using the preparation process in Example 4, 4-fluoro-3-nitrophthalic anhydride and 1-(2-methoxyethyl)-3-amino-2,6-piperidinedione acetate were reacted to prepare 5-fluoro-4-nitro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione as a black solid (0.3 g) (HPLC purity: 90.63%). MS(m/e): 380.21 (M+H+).
- Using the preparation process in Example 7, 5-fluoro-4-nitro-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione was used to give the title compound as a yellow solid (0.137 g) (HPLC purity: 97.59%). Yield: 57.2%.
- 1HNMR (CDCl3, 400 MHz) δ 7.256-7.208 (dd, 1H), 7.158-7.129 (dd, 1H), 5.269 (bs, 2H), 4.959-4.914 (m, 1H), 4.140-3.988 (m, 2H), 3.544-3.512 (m, 2H), 3.341 (s, 3H), 3.000-2.961 (m, 1H), 2.795-2.745 (m, 2H), 2.121-2.081 (m, 1H). MS(m/e): 350.2 (M+H+).
- 4-BOC-amino-7-hydroxyphthalate dimethyl was prepared in accordance with Journal of Organic Chemistry, 62(12), 4088-4096; 1997.
- To a reaction flask were added 3-BOC-amino-6-hydroxyphthalate dimethyl (3.0 g), 1-(2-methoxyethyl)-3-amino-2,6-piperidinedione acetate (4.5 g) and pyridine (60 mL). The reaction flask was heated to 100° C. in an oil bath. The reaction solution was stirred over 40 hours and then cooled to the room temperature. The resultant solution was concentrated to give a crude product. The crude product was purified with silica gel column chromatography to give 4-BOC-amino-7-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione as a yellow solid (2.35 g) (HPLC purity: 95.96%). Yield: 48.8%. MS(m/e): 470.28 (M+Na+).
- 4-BOC-amino-7-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione (2.25 g) was dissolved in dichloromethane (20 mL). To the solution was added tetrahydrofuran (4 mL). The resultant solution was stirred at the room temperature over 6 hours until the reaction was complete. The solution was concentrated under reduced pressure to give a crude product. The crude product was dissolved and purified with methyl tert-butyl ether to give the title compound as brown solid (1.413 g) (HPLC purity: 95.35%). Yield: 77.4%.
- 1HNMR (CDCl3, 400 MHz) δ 7.020-6.998 (d, 1H), 6.858-6.835 (d, 1H), 4.934-4.889 (m, 1H), 4.145-3.995 (m, 2H), 3.555-3.521 (m, 2H), 3.346 (s, 3H), 3.031-2.926 (m, 1H), 2.827-2.742 (m, 2H), 2.140-2.059 (m, 1H). MS(m/e): 348.22 (M+H+).
- To a reaction flask were added 3-amino-N-(2,6-dioxo-3-piperidinyl) phthalimide (2.5 g), 2-chloroethyl methyl sulfide (2.55 g), potassium carbonate (3.8 g), sodium iodide (0.28 g) and N,N-dimethylformamide (35 mL). The reaction flask was heated to 50° C. in an oil bath. The reaction solution was stirred over 20 hours until the reaction was complete. To the reaction solution were added dichloromethane and water to extract. The aqueous phase was back-extracted with dichloromethane twice. The organic phases were combined. The combined organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to give a crude product. The crude product was purified with silica gel column chromatography to give the title compound as a yellow solid (2.111 g) (HPLC purity: 96.68%). Yield: 55.3%.
- 1HNMR (CDCl3, 400 MHz) δ 7.457-7.418 (dd, 1H), 7.180-7.161 (dd, 1H), 6.885-6.863 (dd, 1H), 4.966-4.921 (m, 1H), 4.110-3.973 (m, 2H), 2.994-2.926 (m, 1H), 2.820-2.753 (m, 2H), 2.683-2.646 (t, 2H), 2.144 (s, 3H), 2.125-2.079 (m, 1H). MS(m/e): 348.19 (M+H+).
- To a reaction flask were added 4-amino-2-(1-(2-methylthioethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione (4.85 g), m-chloroperoxybenzoic acid (3.13 g) and dichloromethane (170 mL). The solution was stirred at the room temperature over 18 hours. To the reaction system was added saturated aqueous solution of sodium bicarbonate (100 mL) to extract. The aqueous phase was back-extracted with dichloromethane (150 mL×3). The organic phases were combined. The combined organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to give a crude product. The crude product was purified with silica gel column chromatography to give the title compound 4-amino-2-(1-(2-methylsulfinylethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione (0.846 g) (HPLC purity: 95.09%). Yield: 16.7%.
- 1HNMR (CDCl3, 400 MHz) δ 7.462-7.423 (dd, 1H), 7.172-7.155 (d, 1H), 6.895-6.874 (d, 1H), 4.974-4.931 (m, 1H), 4.371-4.192 (m, 2H), 3.073-2.909 (m, 3H), 2.827-2.696 (m, 2H), 2.650-2.647 (d, 3H), 2.144-2.104 (m, 1H). MS(m/e): 364.22 (M+H+).
- In accordance with the preparation process in Example 12, 4-amino-2-(1-(2-methylthioethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione was used to give the title compound as a yellow solid (1.78 g) (HPLC purity: 99.47%). Yield: 33.6%.
- 1HNMR (CDCl3, 400 MHz) δ 7.470-7.431 (dd, 1H), 7.184-7.167 (d, 1H), 6.896-6.876 (d, 1H), 4.988-4.943 (m, 1H), 4.400-4.231 (m, 2H), 3.311-3.277 (t, 2H), 2.999 (s, 3H), 3.012-2.932 (m, 1H), 2.834-2.697 (m, 2H), 2.153-2.110 (m, 1H). MS(m/e): 380.23 (M+H+).
- 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione was prepared in accordance with PCT Int. Appl., 2006105697, 12 Oct. 2006.
- 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione (5 g) was dissolved in tetrahydrofuran (100 mLl) under argon atmosphere. The solution was cooled to −78° C. To the solution was slowly added dropwise lithium hexamethyldisilazide (40 mL). After addition, the resultant solution was stirred over 1 hour. To the solution was added N-fluorobenzenesulfonimide (11.67 g in 30 mL of tetrahydrofuran). After addition, the resultant solution was stirred over 1 hour. The resultant solution was slowly heated to the room temperature and reacted overnight. To the reaction mixture were added saturated aqueous solution of ammonium chloride (150 mL) and ethyl acetate (150 mL). The solution was separated. The aqueous phase was extracted with ethyl acetate (100 mL). The organic phases were combined. The combined organic phase was washed with saturated aqueous solution of sodium chloride (200 mL), dried over anhydrous sodium sulfate and filtered. The organic phase was concentrated. The residue was purified with column chromatography (ethyl acetate/petroleum ether=1/3) to give the title compound as a yellow solid (968 mg) (HPLC purity: 97.20%). Yield: 18.4%.
- 1HNMR (CDCl3, 400 MHz) δ 7.461-7.499 (dd, 1H), 7.171-7.153 (d, 1H), 6.931-6.899 (d, 1H), 4.193-4.024 (m, 2H), 3.670-3.640 (t, 2H), 3.606-3.5558 (m, 1H), 3.020 (s, 3H), 2.371-2.960 (m, 1H), 2.656-2.555 (m, 1H), 2.433-2.342 (m, 1H). MS(m/e): 372.22 (M+Na+).
- 3-amino-3-methylpiperidin-2,6-dione hydrochloride was prepared in accordance with PCT Int. Appl., 2006081251, 3 Aug. 2006.
- Using the preparation process in Example 4, 3-amino-3-methylpiperidin-2,6-dione hydrochloride and 3-nitrophthalic anhydride were reacted to give 2-(3-methyl-2,6-dioxopiperidin-3-yl)-4-nitroisoindolin-1,3-dione as a white solid (2.7 g) (HPLC purity: 66.03%). Yield: 69.1%. MS(m/e): 318.12 (M+H+).
- Using the preparation process in Example 11, 2-(3-methyl-2,6-dioxopiperidin-3-yl)-4-nitroisoindolin-1,3-dione was used to prepare 4-nitro-2-(1-(2-methoxyethyl)-3-methyl-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione as a yellow solid (0.736 g) (HPLC purity: 96.45%). Yield: 28.3%. MS(m/e): 376.26 (M+H+).
- Using the preparation process in Example 7, 4-nitro-2-(1-(2-methoxyethyl)-3-methyl-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione was used to give the title compound as yellow solid (0.572 g) (HPLC purity: 94.51%). Yield: 84.1%.
- 1HNMR (CDCl3, 400 MHz) δ 7.430-7.391 (t, 1H), 7.104-7.086 (d, 1H), 6.854-6.833 (d, 1H), 4.112-4.074 (m, 2H), 3.615-3.580 (m, 2H), 3.373 (s, 3H), 2.844-2.793 (m, 1H), 2.734-2.690 (m, 2H), 2.046-1.993 (m, 1H), 1.969 (s, 3H). MS(m/e): 368.22 (M+Na+). MS(m/e): 368.22 (M+Na+).
- N-((benzyloxy)carbonyl)-glutamic anhydride was prepared in accordance with Archives of Pharmacal Research, 31(7), 834-837; 2008.
- To a reaction flask were added N-((benzyloxy)carbonyl)-glutamic anhydride (19 g), 3-methoxypropylamine (6.4 g), triethylamine (7.3 g), 4-dimethylaminopyridine (0.88 g) and tetrahydrofuran (270 mL). The reaction solution was stirred at the room temperature over 40 hours until the reaction was complete. The resultant reaction was the tetrahydrofuran solution of the product, which was directly used in the next step.
- N,N′-carbonyldiiazole (23.4 g) was added into the above reaction solution in batch. The resultant solution was stirred at the room temperature over 72 hours until the reaction was complete. The solution was concentrated under reduced pressure. To the concentrate was added dichloromethane (500 mL). The resultant solution was washed with 1 N hydrochloric acid (250 mL), saturated aqueous solution of sodium bicarbonate (250 mL) and saturated aqueous solution of sodium chloride (250 mL). The organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to give 1-(3-methoxypropyl)-3-benzyloxyamido-2,6-piperidinedione as a brown oil (23.7 g), which was directly used in the next step. MS(m/e): 357.24 (M+Na+).
- Using the preparation process in Example 4, 1-(3-methoxypropyl)-3-benzyloxyamido-2,6-piperidinedione was used to prepare the title compound as a white solid (0.434 g) (HPLC purity: 97.71%). Yield: 12.5%.
- 1HNMR (CDCl3, 400 MHz) δ 9.411 (bs, 1H), 8.822-8.801 (d, 1H), 7.729-7.689 (dd, 1H), 7.555-7.535 (dd, 1H), 4.943-4.987 (m, 1H), 3.993-3.879 (m, 2H), 3.428-3.397 (t, 2H), 3.304 (s, 3H), 3.005-2.936 (m, 1H), 2.825-2.705 (m, 2H), 2.266 (s, 3H), 2.146-2.092 (m, 1H), 1.880-1.802 (m, 2H). MS(m/e): 410.31 (M+Na+).
- Using the preparation process in Example 4, 1-(3-methoxypropyl)-3-amino-2,6-piperidinedione acetate and 3-fluorophthalic anhydride were reacted to give the title compound as a yellowish sticky product (0.631 g) (HPLC purity: 97.42%). Yield: 31.1%.
- 1HNMR (CDCl3, 400 MHz) δ 7.792-7.743 (m, 1H), 7.715-7.697 (d, 1H), 7.444-7.400 (m, 1H), 4.978-4.932 (m, 1H), 3.988-3.871 (m, 2H), 3.421-3.390 (t, 2H), 3.300 (s, 3H), 3.000-2.938 (m, 1H), 2.851-2.691 (m, 2H), 2.142-2.091 (m, 1H), 1.872-1.797 (m, 2H). MS(m/e): 349.22 (M+H+).
- Using the preparation process in Example 4, 5-nitrophthalic anhydride and 1-(3-methoxypropyl)-3-amino-2,6-piperidinedione acetate were reacted to prepare 5-nitro-2-(1-(3-methoxypropyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione as a yellowish oily product (1.118 g) (HPLC purity: 98.44%). Yield: 20%. MS(m/e): 376.25 (M+H+).
- Using the preparation process in Example 7, 5-nitro-2-(1-(3-methoxypropyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione was used to give the title compound as a yellowish solid (0.697 g) (HPLC purity:97.79%). Yield: 67.7%.
- 1HNMR (CDCl3, 400 MHz) δ 7.624-7.603 (d, 1H), 7.031-7.027 (d, 1H), 6.861-6.835 (dd, 1H), 4.925-4.879 (m, 1H), 3.977-3.863 (m, 2H), 3.421-3.390 (t, 2H), 3.301 (s, 3H), 2.969-2.922 (m, 1H), 2.820-2.676 (m, 2H), 2.108-2.056 (m, 1H), 1.869-1.794 (m, 2H). MS(m/e): 346.24 (M+H+).
- Using the preparation process in Example 16, N-((benzyloxy)carbonyl)-glutamic anhydride was used to prepare 1-(2-ethoxyethyl)-3-benzyloxyamido-2,6-piperidinedione as a brown oily crude product (17.2 g).
- Using the preparation process in Example 4, 1-(2-ethoxyethyl)-3-amino-2,6-piperidinedione acetate and 3-nitrophthalic anhydride were reacted to prepare 4-nitro-2-(1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione as an off-white solid (1.326 g) (HPLC purity: 95.24%). Yield: 39.4%. MS(m/e): 376.23 (M+H+).
- Using the preparation process in Example 7, 4-nitro-2-(1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione was used to prepare 4-amino-2-(1-(2-ethoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione as a yellow solid (0.631 g) (HPLC purity: 94.95%). Yield: 51.7%.
- 1HNMR (CDCl3, 400 MHz) δ 7.450-7.411 (dd, 1H), 7.174-7.156 (d, 1H), 6.881-6.860 (d, 1H), 4.963-4.918 (m, 1H), 4.119-3.994 (m, 2H), 3.575-3.480 (m, 4H), 3.023-2.921 (m, 1H), 2.839-2.714 (m, 2H), 2.140-2.035 (m, 1H), 1.180-1.145 (t, 3H). MS(m/e): 346.24 (M+H+).
- Using the preparation process in Example 4, 1-(2-ethoxyethyl)-3-amino-2,6-piperidinedione acetate and 3-fluorophthalic anhydride were reacted to give the title compound as a yellowish sticky product (1.566 g) (HPLC purity: 98.63%). Yield: 74.7%.
- 1HNMR (CDCl3, 400 MHz) δ 7.792-7.743 (m, 1H), 7.715-7.698 (d, 1H), 7.444-7.400 (m, 1H), 5.019-4.974 (m, 1H), 4.147-3.984 (m, 2H), 3.570-3.475 (m, 4H), 3.045-2.941 (m, 1H), 2.862-2.733 (m, 2H), 2.167-2.087 (m, 1H), 1.178-1.143 (t, 3H). MS(m/e): 349.23 (M+H+).
- Using the preparation process in Example 4, 4-fluorophthalic anhydride and 1-(2-methoxyethyl)-3-amino-2,6-piperidinedione acetate were reacted to give the title compound as a white solid (2.905 g) (HPLC purity: 99.64%). Yield: 77.9%.
- 1HNMR (CDCl3, 400 MHz) δ 7.912-7.880 (dd, 1H), 7.572-7.549 (dd, 1H), 7.457-7.408 (dt, 1H), 5.023-4.978 (m, 1H), 4.144-3.988 (m, 2H), 3.544-3.512 (m, 2H), 3.342 (s, 3H), 3.056-2.933 (m, 1H), 2.859-2.738 (m, 2H), 2.175-2.080 (m, 1H). MS(m/e): 357.20 (M+Na+).
- Using the preparation process in Example 11, 3-amino-N-(2,6-dioxo-3-piperidinyl)-phthalimide and 1-bromo-4-methoxybutane were reacted to give the title compound as a yellow solid (2.625 g) (HPLC purity: 99.02%). Yield: 79.9%.
- 1HNMR (CDCl3, 400 MHz) δ 7.455-7.416 (dd, 1H), 7.178-7.160 (dd, 1H), 6.884-6.863 (dd, 1H), 4.927-4.882 (m, 1H), 3.858-3.816 (m, 2H), 3.402-3.371 (t, 2H), 3.317 (s, 3H), 3.007-2.916 (m, 1H), 2.819-2.685 (m, 2H), 2.117-2.067 (m, 1H), 1.651-1.571 (m, 4H). MS(m/e): 360.28 (M+H+).
- Using the preparation process in Example 4, 3-hydroxyphthalic anhydride and 1-(2-methoxyethyl)-3-amino-2,6-piperidinedione acetate were reacted to give the title compound as a white solid (2.833 g) (HPLC purity: 99.54%). Yield: 80.1%.
- 1HNMR (CDCl3, 400 MHz) δ 7.649-7.609 (dd, 1H), 7.539 (bs, 1H), 7.430-7.412 (d, 1H), 7.214-7.193 (d, 1H), 4.980-4.934 (m, 1H), 4.146-3.991 (m, 2H), 3.549-3.516 (m, 2H), 3.342 (s, 3H), 3.048-2.941 (m, 1H), 2.843-2.724 (m, 2H), 2.165-2.083 (m, 1H). MS(m/e): 333.19 (M+H+).
- Using the preparation process in Example 4, 3-methylphthalic anhydride and 1-(2-methoxyethyl)-3-amino-2,6-piperidinedione acetate were reacted to give the title compound as a white solid (2.348 g) (HPLC purity: 98.36%). Yield: 68.1%.
- 1HNMR (CDCl3, 400 MHz) δ 7.716-7.697 (d, 1H), 7.623-7.586 (t, 1H), 7.508-7.489 (d, 1H), 5.017-4.972 (m, 1H), 4.143-3.996 (m, 2H), 3.547-3.516 (t, 2H), 3.344 (s, 3H), 3.006-2.944 (m, 1H), 2.855-2.732 (m, 2H), 2.698 (s, 3H), 2.153-2.084 (m, 1H). MS(m/e): 353.23 (M+Na+).
- To a reaction flask were added 4-amino-5-hydroxy-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)-isoindolin-1,3-dione (2.5 g), methyl iodide (1.02 g), potassium carbonate (1.99 g) and N,N-dimethylformamide (25 mL). The solution was stirred at the room temperature over 16 hours until the reaction was complete. The solution was added into water at the room temperature. The resultant solution was stirred and filtered. The filter cake was collected as crude product. The crude product was dissolved and purified with methyl tert-butyl ether/ethyl acetate to give the title compound as a yellow solid (1.94 g) (HPLC purity: 96.08%). Yield: 74.6%.
- 1HNMR (CDCl3, 400 MHz) δ 7.180-7.160 (d, 1H), 6.891-6.871 (d, 1H), 5.388 (bs, 2H), 4.954-4.909 (m, 1H), 4.136-3.987 (m, 2H), 3.943 (s, 3H), 3.541-3.511 (t, 2H), 3.340 (s, 3H), 2.983-2.944 (m, 1H), 2.793-2.744 (m, 2H), 2.130-2.035 (m, 1H). MS(m/e): 362.22 (M+H+).
- To a three-neck flask (100 mL) were added 3-nitrophthalic anhydride (5 g, 25.9 mmol), L-glutamine (3.782 g, 25.9 mmol), and acetonitrile (45 mL). The reaction solution was magnetically stirred under argon atmosphere. The reaction solution was refluxed at 90° C. over 14 hours. After the reaction was complete, the solution was cooled. To the solution was added N,N′-carbonyldiiazole (12.591 g, 77.7 mmol) at the room temperature. The solution was stirred at the room temperature until no bubble was released. The resultant solution was reacted over 1 hour in an oil bath of 84° C. The solution was cooled to the room temperature. The solution was added into hydrochloric acid (225 mL, 1 mol/L) with vigorously stirring. The resultant solution was stirred and filtered. The filter cake was dissolved in absolute ethanol (25 mL). The solution was filtered. The resultant solid was dried in vacuo to give 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindolin-1,3-dione (5.125 g) as a yellow product. Yield: 65.3%.
- To a single-neck flask (100 mL) were added 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindolin-1,3-dione (3 g, 9.9 mmol) and N,N-dimethylformamide (45 mL). Sodium hydride (content: 60%, 0.872 g, 21.8 mmol) was added in one portion. The solution was stirred at the room temperature over 15 minutes. To the solution was slowly added dropwise 3-bromopropyl methyl ether (1.8 g, 12 mmol) in N,N-dimethylformamide (4 mL). After addition, the reaction continued over 2.5 hours. The reaction solution was poured into saturated aqueous solution of ammonium chloride (400 mL). The resultant solution was extracted with ethyl acetate (200 mL×3). The organic phases were combined. The combined organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated. The residue was separated with column chromatography to give 4-nitro-2-(1-(3-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione (1.211 g). Yield: 32.3%.
- To a single-neck flask were added 4-nitro-2-(1-(3-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione (1.875 g, 5 mmol), palladium on carbon (10%, 0.4 g), methanol (10 mL), tetrahydrofuran (10 mL). The air was replaced with hydrogen. The solution was stirred at the room temperature and under atmospheric pressure overnight. After the reaction was complete, the solution was filtered with diatomite. The filtrate was concentrated. The residue was separated with column chromatography to give the title compound 4-amino-2-(1-(3-methoxypropyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione (1.135 g). HPLC purity: 96.51%. Yield: 65.8%.
- MS(m/e): 346 (M+H+)
- The Chinese patent No. ZL200510013292.3 discloses the preparation process of 4-amino-2-(1-(2-methoxyethyl)-2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione, which is incorporated herein by reference in its entirety.
- Alternatively, in accordance with the preparation process in Example 27, 3-bromopropyl methyl ether was replaced with 3-bromoethyl methyl ether to prepare the title compound.
- 1HNMR (CDCl3, 600 MHz) δ 7.38 (t, 1H), 7.11 (d, 1H), 6.85 (d, 1H), 5.30 (bs, 2H), 4.95-4.98 (m, 1H), 4.09-4.13 (m, 1H), 4.00-4.04 (m, 1H), 3.52-3.54 (m, 2H), 3.34 (s, 3H), 2.96-2.99 (m, 1H), 2.76-2.75 (m, 1H), 2.78-2.80 (m, 1H), 2.08-2.11 (m, 1H). MS(m/e): 332 (M+H+).
- Wistar rats, male, body weight of 100-120 g.
- 90 male Wistar rats were fasted for 40 hours. A 5% glucose injection was administered subcutaneously during fasting. 60 rats with normal conditions and moderate body weight were selected from the fasting rats. The animals were randomly divided into 6 groups according to the body weight: normal control group, model control group, sulfasalazine group (300 mg/Kg), and the compound in Example 27 groups consisting of 5, 15 and 30 mg/Kg dose groups. There were 10 rats in each group. The animals were anesthetized with ether. A specially made gavage device (made by a rat gavage device having the diameter of 2 mm, which was nested on a mouse gavage device having the diameter of 1 mm) was slowly inserted into the enteric cavity at 8 cm from the anus. The model control group, the sulfasalazine group and the compound in Example 27 groups were administered with 0.5 mL of 50 mg/mL DNBS in 30% ethanol solution. The normal control group was administered with 0.5 mL of 30% ethanol solution. The animals were inverted in anesthesia for 15 minutes after the gavage device was removed. The day when the model was prepared was the first day of the experiment. After 4 hours of DNBS induction, the corresponding drug or the corresponding volume of 1% CMC-Na was administered once per day. The body weights were recorded and the stool characteristics were scored. On the sixth day of the experiment colon tissues were taken from the animals to observe the results of each index.
- The compound in Example 27 and sulfasalazine: Preparation Method: Suspended with 1% CMC-Na, and prepared when it was needed.
-
TABLE 3 Grouped Table DNBS Clysis Administration DNBS Concentration Volume Administration Dose Administration Groups Solvent (mg/mL) (mL/rat) Route (mg/Kg) Regimen Normal 30% 0 0.5 i.g 0 qd × 6 Control Group ethanol Model Control 30% 50 0.5 i.g 0 qd × 6 Group ethanol Sulfasalazine 30% 50 0.5 i.g 300 qd × 6 Group ethanol Compound in 30% 50 0.5 i.g 5 qd × 6 Example 27 ethanol Group 30% 50 0.5 i.g 15 qd × 6 ethanol 30% 50 0.5 i.g 30 qd × 6 ethanol Note: i.g: intragastric administration; qd × 6: once per day, a total of 6 times. - Animals were euthanized on the sixth day of the experiment to observe the results of each index. After the animals were sacrificed, colons were obtained. The adhesion degree of colon was observed and the length of the colon was measured. The ulcer area was calculated after removing the contents in the colon and the weight of the colon tissue was weighed. The colon tissue was longitudinally divided into two parts. One part of the colon tissue was fixed in 10% formalin solution for later use. The other part of the colon tissue was put into the liquid nitrogen to quickly frozen, and then was reserved at −80° C. for the detection of MPO.
-
TABLE 4 Criteria for Adhesion Degree of Colon in Rats Adhesion Degree Point None 0 Mild 1 Severe 2 - Reference: Videla S, Vilaseca J, Medina C, et al. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis [J]. Journal of Pharmacology and Experimental Therapeutics, 2006, 316(2): 940-945.
- Calculation method for ulcer area: length of ulcer point (cm)×width of ulcer point (cm).
- The frozen tissue was ground into powder in liquid nitrogen. An appropriate amount of the powder was weighed and was added into 50 mM potassium phosphate solution (containing 0.5% cetyltrimethylammonium bromide) to give a 25 mg/mL solution. The resultant solution was homogenized by an electric homogenizer. 1 mL of suspension was centrifuged to give a supernatant. 7 μL of the supernatant was added into a 96-well plate and 200 μL of o-dianisidine mixture (containing 0.167 mg/mL o-dianisidine and 0.0006% H2O2 potassium phosphate buffer). OD values of the resultant solution at 0, 30, 60, and 90 s were detected at 450 nm of the microplate reader.
- Test for homogeneity of variance was performed with Spss13.0. Where variance of data was homogeneous (P>0.05), one-way ANOVA LSD test was performed. Where the analysis of variance was significant (P<0.05), then Dunnett's multiple comparison (parameter method) or Kruskal-Wallis non-parametric test was performed. Where the results of Kruskal-Wallis non-parametric test were significant (P<0.05), the Mann-Whitney U test was performed for pairwise comparison.
-
-
TABLE 5 Results of Animal Colon Indexes in Each Group (Mean ± SD) Adhesion Degree Colon Weight Groups (Point) (mg) Normal Control Group 0.0 ± 0.0 1454.3 ± 177.9 Model Control Group 0.7 ± 0.8 2026.1 ± 781.0 Sulfasalazine Group—300 mg/Kg 0.2 ± 0.4 1794.9 ± 242.3 Compound in Example 27 Group—5 mg/Kg 0.4 ± 0.7 1775.7 ± 321.0 Compound in Example 27 Group—15 mg/Kg 0.1 ± 0.3 1668.7 ± 245.3 Compound in Example 27 Group—30 mg/Kg 0.1 ± 0.3 1534.7 ± 156.2 Note: *: compared with normal control group, P < 0.01; #: compared with model control group, P < 0.05. -
TABLE 6 Results of Animal Colon Indexes in Each Group (Mean ± SD) Colon weight Ulcer Colon MPO to length ratio Area Activity Groups (mg/cm) (cm2) (U/mg) Normal Control Group 90.0 ± 9.5 0.0 ± 0.0 1.7 ± 1.2 Model Control Group 145.4 ± 50.1 1.8 ± 1.9 33.4 ± 19.6* Sulfasalazine Group—300 140.6 ± 27.9 0.7 ± 0.6 26.0 ± 14.8 mg/Kg Compound in Example 27 144.2 ± 30.5 0.8 ± 0.9 20.3 ± 19.8 Group—5 mg/Kg Compound in Example 27 127.1 ± 13.7 0.7 ± 0.9 16.7 ± 9.8# Group—15 mg/Kg Compound in Example 27 117.7 ± 19.4 0.3 ± 0.5 15.1 ± 13.0# Group—30 mg/Kg Note: *compared with normal control group, P < 0.05; #compared with model control group, P < 0.05. - Results of colonic tissue-related indexes showed that compared with the normal control group, the colon of the model control group was significantly shortened, the colon tissue was abnormally proliferated and the colon weight was increased. At the same time, the MPO activity of colon tissue was significantly increased, the colon had a larger area of ulcer injury. Sulfasalazine as positive drug at the dose of 300 mg/Kg reduced the colon abnormal proliferation and reduced the colon weight, and had some improvement on colonic ulcers with the reduction of the ulcer area by 60%. The compound in Example 27 at the dose of 5 mg/Kg, 15 mg/Kg and 30 mg/Kg reduced the adhesion degree of colons, reduced the weight of colon tissue and the ulcer degree, and reduced the MPO activity of colon tissue, and thus showed a certain dose effect and a good therapeutic effect without the weight loss of animals. The compound in Example 27 at the dose of 30 mg/Kg reduced the ulcer degree of colon with a reduction of the ulcer area by about 80%, while the MPO activity of colon tissue was significantly reduced (P<0.05), of which the therapeutic effects are better than those of sulfasalazine as positive drug at the dose of 300 mg/Kg.
- 110 male Wistar rats were fasted for 40 hours. A 5% glucose injection (10 mL/Kg) was administered subcutaneously during fasting. 48 rats with normal conditions and moderate body weight were selected from the fasting rats. The animals were randomly divided into 5 groups according to the body weight: normal control group, model control group, sulfasalazine group (300 mg/Kg), dexamethasone group (0.1 mg/Kg), the compound in Example 26 group (30 mg/kg) and the compound in Example 27 group (30 mg/kg), with 8 rats in each group. The animals were anesthetized with isoflurane. A specially made gavage device (made by a rat gavage device having the diameter of 2 mm, which was nested on a mouse gavage device having the diameter of 1 mm) was slowly inserted into the enteric cavity at 8 cm from the anus. The model control group, the compound in Example 26 group and the compound in Example 27 group were administered with 0.5 mL of 50 mg/mL DNBS in 30% ethanol solution. The normal control group was administered with 0.5 mL of 30% ethanol solution. The animals were inverted in anesthesia for 15 minutes after the gavage device was removed. The day when the model was prepared was the first day of the experiment. After 4 hours of DNBS induction, the corresponding drug or the corresponding volume of 1% CMC-Na was administered once per day. On the sixth day of the experiment, the animals were euthanized to observe the results of each index so as to score the colon adhesion degree, measure the length of colon and ulcer area, weigh colon and calculate the colon weight to length ratio.
- The compound in Example 26 and Example 27, sulfasalazine and dexamethasone: Preparation Method: Suspended with 1% CMC-Na, and prepared when it was needed.
-
TABLE 7 Grouped Table DNBS Clysis Administration Number Concentration Volume Administration Dose Administration of Groups (mg/mL) (mL/rat) Route (mg/Kg) Regimen Animals Normal Control 0 0.5 i.g 0 qd × 6 8 Group Model Control 50 0.5 i.g 0 qd × 6 8 Group Sulfasalazine 50 0.5 i.g 300 qd × 6 8 Group Dexamethasone 50 0.5 i.g 0.1 qd × 6 8 Group Compound in 50 0.5 i.g 30 qd × 6 8 Example 27 Group Compound in 50 0.5 i.g 30 qd × 6 8 Example 26 Group Note: qd × 6: once per day, a total of 6 times. - Levene's Test for homogeneity of data was performed with Spss. Where the data were homogeneous (P>0.05), one-way ANOVA LSD test was performed. Where the analysis of variance was significant (P≤0.05), Dunnett's multiple comparison (parameter method) was performed. Where the results of Levene's Test were significant (P≤0.05), Kruskal-Wallis nonparametric test was performed. Where the results of Kruskal-Wallis nonparametric test were significant (P≤0.05), Mann-Whitney U test was performed for pairwise comparison.
-
-
TABLE 8 Results of Animal Colon Indexes in Each Group (Mean ± SD) Colon Adhesion Length Colon Weight Degree Ulcer Area Groups (cm) (mg) (Points) (cm2) Normal Control 15.1 ± 0.9 1406.3 ± 83.7 0.0 ± 0.0 0.0 ± 0.0 Group Model Control 12.6 ± 1.3** 1863.3 ± 406.0* 0.9 ± 0.6 3.3 ± 1.4** Group Sulfasalazine 13.2 ± 2.5 1776.1 ± 280.7 0.8 ± 0.7 1.6 ± 1.2# Group Dexamethasone 14.2 ± 0.9 1496.0 ± 450.0# 0.3 ± 0.5 1.4 ± 1.5# Group Compound in 13.7 ± 1.4 1628.3 ± 185.5 0.3 ± 0.5 1.1 ± 0.9## Example 26 Group Compound in 12.9 ± 2.3 1737.9 ± 410.6 0.9 ± 0.8 2.0 ± 1.9 Example 27 Group Note: *compared with normal control group, P < 0.05; **compared with normal control group, P < 0.01; #compared with model control group, P < 0.05, ##compared with model control group, P < 0.01. - The results of this experiment showed that after the animals were induced by DNBS in ethanol solution, the growth rate of the body weight was lower than that of the normal control group. On the fourth day of the experiment, the growth rate of the body weight of the animals in the sulfasalazine group and the compound in Example 26 group and the compound in Example 27 group was higher than that in the model control group, while the growth of the body weight of the animals in the dexamethasone group were slower, which indirectly implied the improvement effects of the drugs on the colonic injury.
- The results of fecal characteristics showed that diarrhea symptoms were observed in all groups of DNBS-induced animals. On the fifth day of experiment, symptoms of diarrhea and liquid stools of animals in each administration group were slightly improved compared with the model control group.
- Colon indexes showed that the area of colonic ulcer and the weight of colon of model control group were significantly higher than those of normal control group (P<0.05), and the colon was significantly shortened. Compared with model control group, there was significant reduction in the area of colonic ulcer in each administration group (P<0.05).
- In view of the above results, the compound in Example 26 and the compound in Example 27 have good therapeutic effects on the improved model.
- 102 male Wistar rats were fasted for 40 hours. A 5% glucose injection (10 mL/Kg) was administered subcutaneously during fasting. 72 rats with normal conditions and moderate body weight were selected from the fasting rats. The animals were randomly divided into 9 groups according to the body weight (see Table 9. Grouped Table).
- The animals were anesthetized with ether after 40 hours fasting. A specially made gavage device was slowly inserted into the enteric cavity at 8 cm from the anus. The model control group and each test group were administered with 0.5 mL of 50 mg/mL DNBS in 30% ethanol solution. The normal control group was administered with 0.5 mL of 30% ethanol solution. The animals were inverted in anesthesia for 15 minutes. The day when the model was prepared was day 0 of the experiment. After 4 hours of DNBS induction, the corresponding drug or the corresponding volume of 1% CMC-Na was administered once per day. On day 7 of the experiment, the animals were euthanized to score the colon adhesion degree, measure the length of colon and ulcer area, weigh colon and calculate the colon weight to length ratio.
-
TABLE 9 Grouped Table DNBS Clysis Administration Number DNBS Concentration Volume Administration Dose Administration of Groups Solvent (mg/ml) (ml/rat) Route (mg/Kg) Regimen Animals Normal 30% 0 0.5 — — — 8 Control Group ethanol Model Control 50 0.5 i.g — qd × 7 Group Example 27 30 Example 7 Example 4 Example 21 Example 22 Example 6 Example 16 Note: The compound in each Example was suspended with 1% CMC-Na to prepare a 3 mg/mL of homogenous suspension. The administration volume was 10 mL/Kg. qd × 7: once per day, a total of 7 times. i.g: intragastric administration. - One-way ANOVA analysis of the length of colon and colon weight per length of rats was performed by SPSS22. Statistical analyses between groups were performed. The adhesion degree was scored. Mann-Whitney U non-parametric test was performed on ulcer area. Statistical analyses between groups were performed.
-
TABLE 10 Criteria for Adhesion Degree of Colon in Rats Adhesion Degree Point None 0 Mild 1 Severe 2 -
-
TABLE 11 Table of Body Weights Changes of Experimental Rats over 7 Days (g, Mean ± SD) Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Blank Control 135.7 ± 4.1 150.4 ± 7.4 162.7 ± 12.0 168.1 ± 15.5 172.3 ± 12.8 180.5 ± 15.7 182.7 ± 12.9 197.0 ± 13.1 Group Model Control 139.9 ± 6.6 141.6 ± 10.4 140.8 ± 11.0 137.9 ± 6.6 143.8 ± 7.9 154.0 ± 4.6 158.3 ± 7.7 168.2 ± 14.3 Group Example 27 135.4 ± 4.9 135.2 ± 4.2 136.7 ± 5.0 141.7 ± 7.5 150.1 ± 9.2 159.1 ± 10.3 165.2 ± 10.0 175.8 ± 8.2 Example 7 136.1 ± 2.5 136.7 ± 3.7 137.0 ± 8.7 141.6 ± 11.9 148.2 ± 12.7 159.2 ± 13.2 168.0 ± 15.7 173.5 ± 18.5 Example 4 137.1 ± 6.2 136.2 ± 4.1 138.2 ± 6.9 141.1 ± 8.8 151.8 ± 13.4 162.5 ± 13.0 170.8 ± 13.0 181.0 ± 12.2 Example 21 135.6 ± 6.9 134.4 ± 6.8 133.9 ± 6.8 138.7 ± 6.8 146.4 ± 6.9 157.9 ± 8.9 168.3 ± 4.6 173.5 ± 7.4 Example 22 137.5 ± 7.2 137.0 ± 9.0 139.7 ± 11.2 144.1 ± 12.7 152.6 ± 20.0 162.7 ± 19.0 170.5 ± 17.7 178.3 ± 20.7 Example 6 137.5 ± 5.6 138.1 ± 8.0 141.8 ± 13.1 147.4 ± 16.5 154.5 ± 17.7 164.2 ± 16.2 169.3 ± 18.4 180.9 ± 15.5 Example 16 137.3 ± 1.7 135.9 ± 3.7 137.6 ± 7.0 145.0 ± 9.2 155.2 ± 10.9 166.8 ± 10.2 171.5 ± 15.1 184.3 ± 13.8 -
TABLE 12 Colonic Data of Rats in Each Group Inhibitory Inhibitory rate of Inhibitory Adhesion rate of weight rate of Degree of colon Colon weight increase Ulcer area ulcer area Colon adhesion to length ratio per length of colon of colon (unit: point) (%) (unit: mg/cm) (%) (unit: cm2) (%) Blank Control 0.0 ± 0.0 76 ± 13 0.00 ± 0.00 Group Model Control 1.7 ± 0.5*** 155 ± 56*** 3.09 ± 2.23*** Group Example 27 0.9 ± 0.4# 47.1# 109 ± 12## 58.2## 0.01 ± 0.02## 99.7## Example 22 0.8 ± 0.9# 52.9# 112 ± 40# 54.4# 1.84 ± 2.59 40.5 Example 21 0.9 ± 0.7# 47.1# 104 ± 17## 64.6## 0.93 ± 1.52 70.0 Example 16 1.1 ± 0.8 35.3 114 ± 23# 51.9# 0.84 ± 1.25# 72.8# Example 7 0.9 ± 0.8# 47.1# 127 ± 52 35.4 0.77 ± 1.05 75.1 Example 6 0.6 ± 0.5## 64.7# 99 ± 21## 70.9## 0.34 ± 0.54# 89.0# Example 4 0.6 ± 0.7## 64.7## 125 ± 34 38.0 0.58 ± 0.78# 81.2# Note: ***compared with blank control group, P < 0.001; #compared with model control group, P < 0.05; ##compared with model control group, 0.001 ≤ P < 0.01. - Calculation Formula of Inhibitory rate of weight increase per length: (Colon weight to length ratio in model group−Colon weight to length ratio in administration group)/(Colon weight to length ratio in model group−Colon weight to length ratio in blank group)
- The pathological changes of the colon (adhesion, hyperplasia and ulcer) in the animals can be effectively relieved by the treatment in each experimental group.
- 102 male Wistar rats were fasted for 72 hours. A 5% glucose injection was administered subcutaneously twice during fasting. 88 rats with normal conditions and moderate body weight were selected from the fasting rats. The animals were randomly divided into 11 groups according to the body weight (see Table 11. Grouped Table).
- The animals were anesthetized with ether after 72 hours fasting. A specially made gavage device was slowly inserted into the enteric cavity at 8 cm from the anus. The model control group and each test group were administered with 0.5 mL of 50 mg/mL DNBS in 30% ethanol solution. The normal control group was administered with 0.5 mL of 30% ethanol solution. The animals were inverted in anesthesia for 15 minutes. The day when the model was prepared was day 0 of the experiment. After 4 hours of DNBS induction, the corresponding drug or the corresponding volume of 1% CMC-Na was administered once per day. On day 7 of the experiment, the animals were euthanized to score the colon adhesion degree, measure the length of colon and ulcer area, weigh colon and calculate the colon weight to length ratio.
-
TABLE 13 Grouped Table DNBS Clysis Administration Number DNBS Concentration Volume Administration Dose Administration of Groups Solvent (mg/ml) (ml/rat) Route (mg/Kg) Regimen Animals Normal 30% 0 0.5 — — — 8 Control Group ethanol Model Control 50 0.5 i.g — qd × 7 Group Example 27 30 Example 8 Example 14 Example 24 Example 5 Example 23 Example 10 Example 2 Example 12 Note: The drug in the experiment was suspended with 1% CMC-Na to prepare a 3 mg/mL of homogenous suspension. The administration volume was 10 mL/Kg. i.g: intragastric administration. qd × 7: once per day, a total of 7 times. -
TABLE 14 Criteria for Adhesion Degree of Colon in Rats Adhesion Degree Point None 0 Mild 1 Severe 2 - One-way ANOVA analysis of the length of colon and colon weight per length of rats was performed by SPSS22. Statistical analyses between groups were performed. The adhesion degree was scored. Mann-Whitney U non-parametric test was performed on ulcer area. Statistical analyses between groups were performed.
-
-
TABLE 15 Table of Body Weights Changes of Experimental Rats over 7 Days (g, Mean ± SD) Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Blank Control 117.4 ± 1.6 132.2 ± 3.7 143.1 ± 7.7 153.6 ± 7.7 160.7 ± 7.2 172.3 ± 5.4 170.3 ± 4.3 185.0 ± 5.6 Group Model Control 121.1 ± 4.9 125.7 ± 6.3 121.4 ± 11.6 123.0 ± 8.1 125.3 ± 9.4 129.2 ± 12.5 134.7 ± 9.7 153.9 ± 12.7 Group Example 27 121.7 ± 7.0 125.5 ± 8.4 124.4 ± 8.1 125.8 ± 8.2 133.1 ± 9.2 141.6 ± 12.0 146.7 ± 11.8 156.3 ± 11.0 Example 8 125.3 ± 5.4 128.6 ± 5.3 128.2 ± 9.2 131.6 ± 13.5 136.8 ± 17.4 149.1 ± 16.7 149.7 ± 16.8 164.1 ± 17.9 Example 14 119.3 ± 6.4 126.2 ± 8.7 125.1 ± 10.5 129.5 ± 17.8 136.5 ± 19.7 146.4 ± 19.4 147.6 ± 19.9 165.7 ± 20.8 Example 24 123.5 ± 4.8 129.1 ± 5.5 130.9 ± 10.4 133.2 ± 14.5 135.3 ± 13.6 144.9 ± 12.6 145.9 ± 13.3 165.6 ± 12.1 Example 5 123.4 ± 5.5 126.7 ± 8.9 125.0 ± 11.0 126.9 ± 14.0 133.9 ± 13.3 141.9 ± 14.9 146.9 ± 13.9 159.7 ± 14.3 Example 23 121.9 ± 7.0 126.6 ± 8.5 123.2 ± 9.0 123.9 ± 7.6 136.5 ± 11.8 148.1 ± 14.5 152.1 ± 15.9 166.8 ± 12.8 Example 10 119.7 ± 4.2 122.4 ± 6.7 122.1 ± 8.0 126.6 ± 9.8 136.9 ± 12.5 143.7 ± 18.2 144.9 ± 19.7 160.8 ± 25.7 Example 2 117.9 ± 4.6 122.1 ± 4.6 123.0 ± 8.4 127.1 ± 11.3 132.0 ± 12.4 143.9 ± 11.9 141.5 ± 11.5 162.8 ± 15.8 Example 12 123.7 ± 3.3 129.1 ± 5.1 128.7 ± 6.6 133.9 ± 9.8 141.8 ± 12.0 149.2 ± 11.0 149.5 ± 11.2 167.3 ± 11.3 -
TABLE 16 Colonic Data of Animals in Each Experimental Group Inhibitory Inhibitory rate of Inhibitory Adhesion rate of weight rate of Degree of colon Colon weight increase Ulcer area ulcer area Colon adhesion to length ratio per length of colon of colon (unit: point) (%) (unit: mg/cm) (%) (unit: cm2) (%) Blank Control 0.3 ± 0.5 77 ± 8 0 ± 0 Group Model Control 1.6 ± 0.5*** 162 ± 84*** 2.4 ± 3.2** Group Example 27 — — 106 ± 14 65.9 0.4 ± 0.6 83.3 Example 24 0.8 ± 0.7# 62.2# 99 ± 18 74.1 0.3 ± 0.3 87.5 Example 23 0.8 ± 0.7# 62.2# 105 ± 12 67.1 0.2 ± 0.3# 91.7# Example 14 0.8 ± 0.5# 62.2 102 ± 18 70.6 0.1 ± 0.4# 95.8# Example 12 0.8 ± 0.7# 62.2# 92 ± 16# 82.4# 0.4 ± 0.9 83.3 Example 10 0.5 ± 0.5## 81.1## 93 ± 12# 81.2# 0.2 ± 0.5# 91.7## Example 8 0.9 ± 0.6 52.7 106 ± 13 65.9 0.2 ± 0.4 91.7 Example 5 0.8 ± 0.5# 62.2# 99 ± 14 74.1 0.2 ± 0.5 91.7 Example 2 0.8 ± 0.9 66.9# 120 ± 25 57.6 1.0 ± 1.6 83.3 Note: ***compared with blank control group, P < 0.001; **compared with blank control group, 0.001≤ P < 0.01; #compared with model control group, P < 0.05; ##compared with model control group, 0.001 ≤ P < 0.01. - Calculation Formula of Inhibitory rate of weight increase per length: (Colon weight to length ratio in model group−Colon weight to length ratio in administration group)/(Colon weight to length ratio in model group−Colon weight to length ratio in blank group)
- The pathological changes of the colon (adhesion, hyperplasia and ulcer) in the animals can be effectively relieved by the treatment in each experimental group.
- The mice were fasted one day before the experiment. On the day of the experiment, 6 mice (ICR mice, body weight of 19-21 g, three females and three males) were selected in each experiment group. First of all, one female and one male were selected to orally give 1000 mg/Kg, and observed for 5-10 minutes. If there were no obvious side effects, the remaining 4 animals were orally given the same dose, and observed for 10-15 minutes. If no animal died, the animals were placed in a box to balancedly feed for 7 days. The state was observed and the body weight was recorded daily. The animal grouping plan and the initial dose of the drug were shown in the table below:
-
TABLE 17 Information Table of Animal Groups Administration Administration Drug Number Dose Volume Concentration Solvent of Schedule Groups mg/Kg ml/Kg mg/mL Animals Day 1 Blank — 15 — 1% CMC-Na Three Control females Example 1 1000 66.67 and three Example 8 males Example 3 Example 2 Example 4 Example 24 Day 2 Example 23 Example 10 Example 2 Example 11 Example 20 Example 17 Example 13 Example 12 Example 19 Example 26 Day 3 Example 6 Example 3 Example 9
Observation Indexes within 0-15 Minutes after Administration - Activity: restlessness, hyperactivity
- Nervous system response: tremor, spasm, convulsion, ataxia, posture abnormality, etc.
- Autonomic nerve: exophthalmos, salivation, tears, urination (hematuria), diarrhea, piloerection, breathing, etc.
- Body weight
- State of Animal: lethargy, hyperactivity, excitement, hair loss, diarrhea, abnormal behavior, death, etc.
-
-
TABLE 18 Summary Table of Toxic Response of Tested Animals in 7 Days Summary of toxic response of tested animals in 7 Group Sex Days Example 23 Male Abnormality was not observed in 7 days of the test Female Abnormality was not observed in 7 days of the test Example 10 Male Decrease of activity was observed in all the animals within 30 minutes after administration but activity was recovered within this period. Abnormality was not observed in all the animals from day 2 to 7. Female Decrease of activity was observed in all the animals within 30 minutes after administration but activity was recovered within this period. Abnormality was not observed in all the animals from day 2 to 7. Example 2 Male Slight abnormality of activity was occasionally observed in two animals but activity was recovered within in 30 minutes. Abnormality was not observed in all the animals from day 2 to 7. Female Abnormality was not observed in 7 days of the test Example 11 Male Abnormality was not observed in 7 days of the test Female Decrease of activity was observed in one animal after administration but activity was recovered within 3 minutes. Abnormality was not observed in all the animals from day 2 to 7. Example 20 Male Decrease of activity was observed in one animal 11 minutes after administration but activity was recovered later. Abnormality was not observed in all the animals from day 2 to 7. Female Decrease of activity was observed in two animals in 10 minutes after administration but activity was recovered later. Abnormality was not observed in all the animals from day 2 to 7. Example 17 Male Motor dysfunction in two animals was observed 30 minutes after administration and function was recovered later. Abnormality was not observed in all the animals from day 2 to 7. Female Motor dysfunction in one animal was observed 10 minutes after administration and function was recovered later. Abnormality was not observed in all the animals from day 2 to 7. Example 13 Male Abnormality was not observed in 7 days of the test Female Abnormality was not observed in 7 days of the test Example 12 Male Abnormality was not observed in 7 days of the test Female Abnormality was not observed in 7 days of the test Example 19 Male Severe motor dysfunction in two animals was observed 30 minutes after administration and function was recovered in about 2 hours. Abnormality was not observed in all the animals from day 2 to 7. Female Severe motor dysfunction in three animals was observed 30 minutes after administration and function was recovered in about 2 hours. Abnormality was not observed in all the animals from day 2 to 7. Example 26 Male Abnormality was not observed in 7 days of the test Female Abnormality was not observed in 7 days of the test Example 6 Male Abnormality was not observed in 7 days of the test Female Abnormality was not observed in 7 days of the test Example 3 Male Abnormality was not observed in 7 days of the test Female Abnormality was not observed in 7 days of the test Example 9 Male Abnormality was not observed in 7 days of the test Female Abnormality was not observed in 7 days of the test Note: The dosage is 1000 mg/Kg in Table 18 unless indicated otherwise. “n = 1” indicate the number of the tested animal in the group is one. The number of the tested animal is 3 where “n = 1” is not indicated in the group. Abnormality is not observed where the observation index is not mentioned. -
TABLE 19 Table of Daily Body Weight of Tested Male Mice (g, Mean ± SD) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Blank Control 17.4 ± 1.4 23.1 ± 1.5 24.6 ± 2.0 25.9 ± 1.5 26.9 ± 0.7 27.9 ± 1.5 28.7 ± 1.7 Group Example 1 20.1 ± 1.4 23.8 ± 1.4 24.9 ± 1.0 26.3 ± 1.2 27.7 ± 1.3 29.2 ± 1.4 29.4 ± 1.4 Example 8 18.0 ± 1.3 23.1 ± 0.9 24.6 ± 1.0 25.6 ± 1.7 27.2 ± 2.2 28.2 ± 2.2 29.2 ± 2.6 Example 3 18.0 ± 0.2 22.9 ± 0.3 24.3 ± 0.9 25.2 ± 1.1 27.0 ± 1.3 28.2 ± 1.9 28.5 ± 2.7 Example 4 17.6 ± 0.2 22.2 ± 0.3 23.6 ± 0.6 24.7 ± 0.6 26.7 ± 0.4 27.6 ± 0.8 28.2 ± 0.1 Example 22 17.1 ± 0.3 22.9 ± 0.8 23.5 ± 0.9 25.2 ± 0.5 27.2 ± 1.9 27.1 ± 1.8 27.4 ± 1.9 Example 18 18.2 ± 0.4 23.0 ± 0.7 24.1 ± 0.4 25.6 ± 0.8 28.1 ± 1.1 29.0 ± 1.4 29.0 ± 1.0 Example 24 17.7 ± 0.2 22.3 ± 0.7 24.5 ± 1.0 25.2 ± 1.0 27.2 ± 1.3 28.1 ± 2.0 28.9 ± 1.9 Example 23 19.4 ± 0.8 24.6 ± 1.2 24.5 ± 0.6 24.5 ± 0.6 25.4 ± 1.2 28.1 ± 0.8 29.0 ± 0.8 Example 10 19.4 ± 0.3 24.4 ± 0.6 25.5 ± 0.9 25.5 ± 0.9 26.8 ± 0.9 29.2 ± 0.7 30.3 ± 0.7 Example 2 18.6 ± 0.5 24.1 ± 0.4 24.7 ± 0.2 24.7 ± 0.2 26.2 ± 0.6 28.8 ± 0.5 29.2 ± 0.8 Example 11 19.5 ± 0.6 23.7 ± 0.8 25.4 ± 0.4 25.4 ± 0.4 27.0 ± 0.5 29.0 ± 0.7 29.8 ± 1.0 Example 20 18.8 ± 1.0 24.0 ± 1.1 25.3 ± 1.2 25.3 ± 1.2 26.7 ± 1.2 29.0 ± 1.1 29.3 ± 0.7 Example 17 19.0 ± 0.7 24.0 ± 0.7 24.6 ± 0.8 24.6 ± 0.8 26.1 ± 0.7 28.1 ± 0.6 29.3 ± 1.0 Example 13 19.6 ± 0.7 23.1 ± 0.6 24.4 ± 0.9 24.4 ± 0.9 26.5 ± 0.5 28.3 ± 1.3 28.4 ± 0.8 Example 12 18.5 ± 0.2 24.3 ± 0.6 24.9 ± 0.1 24.9 ± 0.1 26.1 ± 0.7 27.8 ± 0.7 28.5 ± 0.7 Example 19 18.9 ± 1.2 20.7 ± 1.1 21.3 ± 0.6 25.0 ± 2.0 24.8 ± 1.9 26.5 ± 1.9 27.7 ± 2.2 Example 26 18.7 ± 0.8 23.4 ± 0.5 25.0 ± 0.6 26.6 ± 1.4 27.3 ± 1.3 28.3 ± 1.3 28.8 ± 1.4 Example 6 18.4 ± 0.6 21.5 ± 0.9 21.6 ± 1.3 25.5 ± 0.5 25.9 ± 0.9 26.9 ± 1.1 27.1 ± 1.1 Example 3 18.8 ± 0.7 23.3 ± 0.1 24.3 ± 0.1 25.6 ± 0.7 26.9 ± 0.8 27.9 ± 0.9 28.6 ± 0.4 Example 9 18.3 ± 0.7 23.6 ± 0.7 24.1 ± 1.0 25.9 ± 1.1 27.2 ± 0.5 26.9 ± 1.4 27.9 ± 1.5 -
TABLE 20 Table of Daily Body Weight of Tested Female Mice (g, Mean ± SD) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Blank Control 17.4 ± 1.4 22.2 ± 0.3 23.4 ± 0.7 23.1 ± 0.2 24.3 ± 1.6 24.7 ± 1.6 24.1 ± 1.1 Group Example 1 18.5 ± 0.1 22.8 ± 0.3 23.2 ± 0.7 24.0 ± 0.2 25.3 ± 1.6 25.7 ± 1.6 27.1 ± 1.1 Example 8 18.9 ± 0.9 22.9 ± 0.9 24.3 ± 0.7 24.3 ± 1.1 25.3 ± 1.4 25.8 ± 1.5 26.0 ± 2.5 Example 3 18.8 ± 0.4 22.1 ± 1.2 22.7 ± 0.8 23.0 ± 1.4 23.7 ± 1.9 24.1 ± 1.2 24.4 ± 1.8 Example 4 18.4 ± 0.4 21.8 ± 0.5 23.2 ± 0.6 23.5 ± 1.2 24.7 ± 0.9 24.2 ± 1.2 24.0 ± 0.8 Example 22 18.5 ± 0.6 21.8 ± 0.3 22.9 ± 0.4 24.0 ± 1.0 25.0 ± 0.4 25.3 ± 0.6 25.6 ± 0.2 Example 18 18.4 ± 0.7 22.5 ± 0.8 23.8 ± 1.1 24.8 ± 1.5 24.8 ± 0.6 25.4 ± 0.7 25.2 ± 1.1 Example 24 18.4 ± 0.7 22.4 ± 1.0 23.4 ± 1.0 23.6 ± 0.9 24.3 ± 0.6 24.7 ± 0.6 24.8 ± 1.5 Example 23 19.1 ± 0.6 22.4 ± 0.4 23.0 ± 0.1 23.0 ± 0.1 24.6 ± 0.4 24.8 ± 0.7 24.6 ± 0.4 Example 10 19.2 ± 0.5 21.9 ± 0.4 22.4 ± 0.2 22.4 ± 0.2 22.9 ± 0.6 24.1 ± 1.5 24.2 ± 1.8 Example 2 19.2 ± 0.5 22.7 ± 0.6 23.2 ± 0.5 23.2 ± 0.5 24.4 ± 0.2 24.6 ± 1.1 24.5 ± 1.9 Example 11 18.1 ± 0.2 21.7 ± 0.2 22.4 ± 0.1 22.4 ± 0.1 23.5 ± 0.4 23.2 ± 0.8 23.2 ± 0.9 Example 20 18.7 ± 0.4 21.6 ± 1.0 22.1 ± 1.0 22.1 ± 1.0 23.0 ± 1.4 23.3 ± 0.2 23.7 ± 0.8 Example 17 18.6 ± 1.0 21.9 ± 0.4 22.7 ± 0.4 22.7 ± 0.4 23.0 ± 0.4 23.1 ± 1.0 22.7 ± 1.2 Example 13 18.8 ± 1.1 21.3 ± 0.3 21.8 ± 0.4 21.8 ± 0.4 23.0 ± 0.5 23.2 ± 0.9 23.6 ± 0.9 Example 12 18.7 ± 0.7 21.8 ± 0.6 22.6 ± 0.1 22.6 ± 0.0 23.7 ± 0.6 25.3 ± 1.0 25.7 ± 1.6 Example 19 18.0 ± 0.6 20.7 ± 1.1 21.3 ± 0.6 22.8 ± 0.3 23.2 ± 0.7 23.3 ± 1.2 23.0 ± 1.7 Example 26 18.0 ± 0.7 21.9 ± 0.3 22.1 ± 0.5 22.4 ± 0.2 22.7 ± 0.3 22.6 ± 0.3 22.4 ± 0.2 Example 6 17.5 ± 0.9 21.5 ± 0.9 21.6 ± 1.3 22.0 ± 1.2 22.3 ± 1.9 22.4 ± 2.3 22.9 ± 2.0 Example 3 18.3 ± 0.4 21.7 ± 0.2 22.3 ± 0.2 22.6 ± 0.8 23.0 ± 1.4 22.6 ± 1.3 22.7 ± 0.4 Example 9 17.5 ± 0.6 22.1 ± 0.9 22.1 ± 0.7 22.8 ± 0.8 22.8 ± 1.0 22.7 ± 1.6 23.6 ± 1.7 - The body weight of the animals in each group had a trend of increase with slight fluctuations. Each compound had no side effects on the change of the body weights of the mice at the dosage of 1000 mg/Kg.
- All the patents, patent application publications, patent applications and non-patent literatures as cited in the present disclosure are incorporated herein by reference in their entirety.
- It is to be understood that the foregoing description relates to exemplary embodiments of the present application and that modifications may be made without departing from the spirit and scope of the present application as set forth in the claims.
Claims (22)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611041317.5 | 2016-11-24 | ||
CN201611041317 | 2016-11-24 | ||
PCT/CN2017/112669 WO2018095378A1 (en) | 2016-11-24 | 2017-11-23 | Piperidine-2,6-diketone derivative and treatment for crohn's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
US20190352277A1 US20190352277A1 (en) | 2019-11-21 |
US20220372013A2 true US20220372013A2 (en) | 2022-11-24 |
Family
ID=62194806
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/464,228 Pending US20220372013A2 (en) | 2016-11-24 | 2017-11-23 | Piperidine-2,6-dione derivatives and crohn's disease treating |
US16/464,224 Active US11485724B2 (en) | 2016-11-24 | 2017-11-23 | Piperidine-2,6-dione derivatives and ulcerative colitis treating |
US17/832,518 Active US11873287B2 (en) | 2016-11-24 | 2022-06-03 | Piperidine-2,6-dione derivatives and ulcerative colitis treating |
US18/533,755 Pending US20240132466A1 (en) | 2016-11-24 | 2023-12-08 | Piperidine-2,6-dione derivatives and ulcerative colitis treating |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/464,224 Active US11485724B2 (en) | 2016-11-24 | 2017-11-23 | Piperidine-2,6-dione derivatives and ulcerative colitis treating |
US17/832,518 Active US11873287B2 (en) | 2016-11-24 | 2022-06-03 | Piperidine-2,6-dione derivatives and ulcerative colitis treating |
US18/533,755 Pending US20240132466A1 (en) | 2016-11-24 | 2023-12-08 | Piperidine-2,6-dione derivatives and ulcerative colitis treating |
Country Status (7)
Country | Link |
---|---|
US (4) | US20220372013A2 (en) |
EP (2) | EP3546450A4 (en) |
JP (2) | JP7143295B2 (en) |
CN (2) | CN108101887A (en) |
AU (2) | AU2017366514B2 (en) |
CA (2) | CA3045703C (en) |
WO (2) | WO2018095377A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3546450A4 (en) | 2016-11-24 | 2020-06-10 | Tianjin Hemay Bio-Tech Co., Ltd | Piperidine-2,6-dione derivative and treatment for ulcerative colitis |
CN108727319A (en) * | 2018-09-05 | 2018-11-02 | 常州大学 | A kind of preparation method of 3- nitrophthalic acids acid anhydride |
CN109293631B (en) * | 2018-11-30 | 2020-05-08 | 常州制药厂有限公司 | Preparation method of 3-amino-N- (2, 6-dioxo-3-piperidyl) -phthalimide compound |
GB202002926D0 (en) * | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
CN111320604B (en) * | 2020-04-22 | 2021-02-09 | 牡丹江医学院 | Compound for treating oral mucosa diseases of children, preparation method and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2172474B1 (en) | 2001-03-01 | 2004-01-16 | Fundacion Universitaria San Pa | GLUTARIMIDE DERIVATIVES AS THERAPEUTIC AGENTS. |
EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
CN100488959C (en) * | 2003-03-27 | 2009-05-20 | 天津和美生物技术有限公司 | Water soluble thalidomide derivative |
US7973057B2 (en) * | 2003-09-17 | 2011-07-05 | The United States Of America As Represented By The Department Of Health And Human Services | Thalidomide analogs |
EP1848433A2 (en) | 2005-01-25 | 2007-10-31 | Celgene Corporation | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione |
CN100383139C (en) * | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | Piperidine-2,6-dione derivatives capable of inhibiting cell from releasing tumor necrosis factor |
CN1961876A (en) * | 2005-11-08 | 2007-05-16 | 北京恩华医药研究院 | Use of phthalimide derivative in preparation of medicament for resisting angiogenesis |
EP2582836B1 (en) | 2010-06-18 | 2018-03-07 | Taiho Pharmaceutical Co., Ltd. | Prpk-tprkb modulators and uses thereof |
AU2014248263A1 (en) | 2013-04-02 | 2015-10-15 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
EP3546450A4 (en) | 2016-11-24 | 2020-06-10 | Tianjin Hemay Bio-Tech Co., Ltd | Piperidine-2,6-dione derivative and treatment for ulcerative colitis |
-
2017
- 2017-11-23 EP EP17874499.1A patent/EP3546450A4/en active Pending
- 2017-11-23 CN CN201711185728.6A patent/CN108101887A/en active Pending
- 2017-11-23 JP JP2019528110A patent/JP7143295B2/en active Active
- 2017-11-23 WO PCT/CN2017/112668 patent/WO2018095377A1/en unknown
- 2017-11-23 CA CA3045703A patent/CA3045703C/en active Active
- 2017-11-23 JP JP2019528114A patent/JP7143296B2/en active Active
- 2017-11-23 CA CA3049161A patent/CA3049161C/en active Active
- 2017-11-23 WO PCT/CN2017/112669 patent/WO2018095378A1/en unknown
- 2017-11-23 CN CN201711184758.5A patent/CN108101886A/en active Pending
- 2017-11-23 US US16/464,228 patent/US20220372013A2/en active Pending
- 2017-11-23 EP EP17873820.9A patent/EP3546449A4/en active Pending
- 2017-11-23 AU AU2017366514A patent/AU2017366514B2/en active Active
- 2017-11-23 US US16/464,224 patent/US11485724B2/en active Active
- 2017-11-23 AU AU2017366515A patent/AU2017366515B2/en active Active
-
2022
- 2022-06-03 US US17/832,518 patent/US11873287B2/en active Active
-
2023
- 2023-12-08 US US18/533,755 patent/US20240132466A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3546450A1 (en) | 2019-10-02 |
AU2017366515B2 (en) | 2021-01-21 |
US11873287B2 (en) | 2024-01-16 |
WO2018095377A1 (en) | 2018-05-31 |
US20190389835A1 (en) | 2019-12-26 |
CN108101887A (en) | 2018-06-01 |
JP2020500205A (en) | 2020-01-09 |
EP3546450A4 (en) | 2020-06-10 |
CN108101886A (en) | 2018-06-01 |
CA3045703A1 (en) | 2018-05-31 |
CA3049161C (en) | 2023-03-07 |
JP2020500204A (en) | 2020-01-09 |
US11485724B2 (en) | 2022-11-01 |
US20240132466A1 (en) | 2024-04-25 |
CA3049161A1 (en) | 2018-05-31 |
EP3546449A1 (en) | 2019-10-02 |
EP3546449A4 (en) | 2020-06-10 |
WO2018095378A1 (en) | 2018-05-31 |
AU2017366514B2 (en) | 2021-01-21 |
AU2017366514A1 (en) | 2019-06-13 |
CA3045703C (en) | 2021-11-02 |
AU2017366515A1 (en) | 2019-06-13 |
JP7143295B2 (en) | 2022-09-28 |
US20190352277A1 (en) | 2019-11-21 |
US20220306600A1 (en) | 2022-09-29 |
JP7143296B2 (en) | 2022-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11873287B2 (en) | Piperidine-2,6-dione derivatives and ulcerative colitis treating | |
ES2772754T3 (en) | Pemafibrate for use in the treatment of non-alcoholic fatty liver disease | |
WO2020177744A1 (en) | Salicylic acid berberine-type alkaloid quaternary ammonium compound and use thereof for preparing medicines | |
EP1968595A2 (en) | Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs | |
CN103420942B (en) | Second, butyrylcholine esterase had dual restraining activities compound | |
US20220288084A1 (en) | Nucleoside derivative for preventing and treating inflammation and application thereof | |
US10869875B2 (en) | Oxysterols and Hedgehog signaling | |
CN114621229A (en) | Compounds or compositions for treating or preventing feline infectious peritonitis | |
WO2006007794A1 (en) | Cis-1,2-substituted stilbene derivates and the use thererof for manufacturing medicaments for treating medicaments for treating and/or preventing diabetes | |
WO2022194136A1 (en) | Diphenyl alkane compound and preparation method therefor, and pharmaceutical composition and use thereof | |
EP3368543B1 (en) | Oxysterols and hedgehog signaling | |
KR102646322B1 (en) | Isoindole derivatives | |
BR112020022190A2 (en) | crystal form of thiophene derivative | |
US11639332B2 (en) | Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases | |
CN106265677B (en) | A kind of pharmaceutical composition and its application preventing and treating ulcerative colitis | |
US20200369594A1 (en) | Compounds comprising short-chain fatty acid moieties and compositions and methods thereof | |
WO2021164053A1 (en) | Pyrido[2,3-d]pyrimidine hiv-1 reverse transcriptase inhibitor, preparation method therefor and application thereof | |
CN115073446A (en) | Berberine type alkaloid oxidized pyrazine formic acid quaternary ammonium salt and application thereof in preparing medicines | |
WO2015180693A1 (en) | Bismuth(iii)dithiocarbamate complex and preparation method and use thereof | |
JPS6254423B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TIANJIN HEMAY BIO-TECH CO., LTD, CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHANG, HESHENG;ZENG, GUANGHUAI;REEL/FRAME:049314/0116 Effective date: 20190517 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: GANZHOU HEMAY PHARMACEUTICAL, CO., LTD, CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TIANJIN HEMAY BIO-TECH CO., LTD;REEL/FRAME:053033/0290 Effective date: 20200618 Owner name: TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD, CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TIANJIN HEMAY BIO-TECH CO., LTD;REEL/FRAME:053033/0290 Effective date: 20200618 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |